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ANALYSIS OF THE STREPTOCOCCAL HEMOPROTEIN RECEPTOR: A ROLE IN
VIRULENCE AND HOST DEFENSE

by

YA-SHU HUANG

Under the Direction of Zehava Eichenbaum

ABSTRACT
Group A streptococcus (GAS) is an important pathogen that produces a wide spectrum of
suppurative infections and autoimmune sequelae in humans, ranging from less complex
pharyngitis, impedigo to more severe manifestations such as necrotizing fasciitis, toxic shock
syndrome, rheumatic fever and glomerulonephritis. The worldwide burden of GAS infections
and sequelae is considerable, but an immunization program that defends against the hypervariable GAS is missing. The streptococcal hemoprotein receptor (Shr), is an iron-regulated

protein involved in heme acquisition. An unspecified region in the amino terminus of Shr
mediates the interactions with hemoglobin and two protein modules named NEAT1 and NEAT2
bind heme. In this study, we analyzed the molecular structure and function of Shr, investigated
its antigenic properties and role in GAS disease production. We demonstrated that Shr is a new
type of GAS adhesin that contributes to the pathogen interactions with extracellular matrix
(ECM) proteins. Shr enabled bacterial adherence to host cells and was important for GAS
virulence in vivo. Immunizations with Shr protein by intraperitoneal or intranasal administration
conferred resistance to systemic GAS challenge in mice. Shr antiserum allowed bacterial
opsonization and defended against GAS diseases in a murine model for passive vaccination.
Studies with isolated Shr domains localized ECM-binding to the NEAT domains and showed
that most of the protein is exposed on the bacterial surface. In addition, Shr N-terminal region
and both of the NEAT modules elicited strong antibody response in rabbits. In conclusion, Shr is
a protective antigen that contributes to GAS pathogenesis by facilitating both heme uptake and
bacterial adherence. Since Shr is conserved among GAS strains and other pyogenic streptococci,
this study demonstrates that Shr may be used to develop a vaccine against GAS strains and
related pathogens.

INDEX WORDS: Streptococcus pyogenes, Sia operon, Adherence, Adhesin, Fibronectin,
MSCRAMM, NEAT domain, Virulence, Immunization, Vaccine
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GENERAL INTRODUCTION
Bacterial adherence to the host mucosal and cutaneous surfaces is a critical step in the
establishment of most infections. Successful colonization requires from pathogens to efficiently
compete with the resident microbial populations for resources and space and to resist clearance
by the host defense mechanisms. The digestive tract for example, is protected by the washing
actions of the saliva and the bowel movements, which exclude bacteria with mechanic forces.
The ciliated cells in the upper respiratory tract repulse microbial invaders by electrostatic forces
and propel those that are trapped to the mucus away from the epithelial surfaces (Cunningham
2000). Surface adhesins with high affinity to molecules that are found on the host cells or
extracellular matrix (ECM) are used by pathogenic bacteria to firmly attach and persist in
desirable sites. In addition to attachment, some bacterial adhesins play additional roles in
virulence and may also contribute to immune escape or nutrient acquisition, for example. The
focus of this study is Group A Streptococcus (GAS), also known as Streptococcus pyogenes.
GAS is an important bacterial pathogen that imposes a significant toll on human health
worldwide. We hypothesized that an exported protein in GAS, named Shr (for Streptococcal
Hemoprotein Receptor), is involved in adherence in addition to its previously described role in
iron uptake. We inferred that the pleiotropic Shr protein has a significant impact on GAS
virulence and is a likely candidate for vaccine development. This dissertation describes the
analysis of Shr structure/function, its role in GAS disease process and illustrates its promise as a
vaccine target. In this introduction, we provide an overview of bacterial adhesins with emphasis
on the mechanisms used by Gram-positive pathogens, offer background information as for the
pathology and epidemiology of streptococcal diseases and summarize the current status of
vaccine development against GAS.
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Bacterial adherence and pathogenesis
Bacterial pathogens express surface molecules that mediate binding to the host and thus facilitate
colonization and the formation of microbial communities. The structure and location of bacterial
adhesins are impacted by the configuration of the cell envelope, which is different between
Gram-positive and Gram-negative organisms. In Gram-negative bacteria, adhesins are often
anchored to the outer membrane, which serves as the cell exterior (enclosing on a thin
peptidoglycan layer in the periplasmic space). In Gram-positive organisms, adhesins are often
covalently bound to the thick cell wall, which is exposed to the extracellular environment
(Abbot, Smith et al. 2007). Other Gram-positive adhesins span the peptidoglycan layer and have
one end outside of the cell wall and the other embedded in the inner membrane via a lipid moiety
or by a transmembrane segment. Because of their surface exposure, bacterial molecules that
mediate adherence are also available for other interactions with the host. For example, adhesins
may communicate with components of the immune system and shape antibody and cytokine
productions by the host.

Several independent adhesins can work synergistically to enhance the attachment of a single
bacterium. In fact, the simultaneous production of a different adhesin combination at separate
disease stages enables the bacterium to colonize the variety of niches that it encounters during
the infection process. The role of a particular adhesin, however, may be difficult to demonstrate
experimentally because of this redundancy. In summary, while not all of the adhesins produced
by an individual pathogen are essential for causing diseases, together, these molecules act to
increase the effectiveness of a single pathogen and enhance its ability to colonize the host
(Nobbs, Lamont et al. 2009).
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Host extracellular matrix (ECM) molecules
Cells in the mammalian host produce and release various macromolecules that together form a
complex network named the extracellular matrix (ECM). Cells bind to the ECM via specific
receptors such as integrins and benefit from the structural support it provides (Fig. 1). In addition
to offering strength, the ECM maintains tissue elasticity. The proteins that make up the ECM are
typically large and multifunctional. Most of them are constructed in a modular fashion and
contain multiple binding surfaces that facilitate multimerization and interactions with a wide
range of macromolecules (Campbell 2003). Collagen, the most plentiful structural protein found
in the host, is the major structural component of the ECM. Collagen forms a variety of interstitial
(collagen types I, II, III) and basement (collagen type V) networks found in different tissue types.

Several glycoproteins, proteoglycans, hyaluronan and other components associate with the basic
collagen networks to form the massive ECM (Cossart, Boquet et al. 2004). Gram-positive
pathogens often choose to interact with the host ECM for adherence purpose (Kreikemeyer,
Klenk et al. 2004; Hauck and Ohlsen 2006). In addition to specific interactions with immobilized
components of the ECM, some bacterial adhesins target soluble components of the matrix. These
soluble proteins then serve as an intermediate bridge between the bacterium and cognate
receptors on the host cell surfaces. In some cases, bacterial binding to a host surface receptor
(directly or via a soluble ECM component) initiates a signaling cascade in the host cell that leads
to bacterial uptake. Similar mechanism allows bacteria to invade phagocytic cells while avoiding
the phagosome and the phagolysosome (Ozeri, Rosenshine et al. 1998; Hauck and Ohlsen 2006;
Caswell, Lukomska et al. 2007).

4

Figure 1. An illustration of some of the proteins and complex in the ECM network.
In the extracellular spaces, collagen is the main structural component. Several glycoproteins,
proteoglycans, hyaluronan and other components associate with the basic collagen networks to
form the massive ECM network. Inside the cell, actin filaments are the major structural
component. The linking of intra- and extra- cellular networks is accomplished in diverse ways.
For example, the ECM protein fibronectin binds both to collagen and to extracellular receptors
such as integrins and syndecan, as illustrated above. (Figure adopted from Campbell, 2003)
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The ECM molecules that serve as targets for bacterial adhesion include collagen, fibronectin,
fibrinogen, vitronectin, laminin, elastin and glycosaminoglycans. Fibronectin is a large
glycoprotein, which exists in a soluble form in the plasma and as a fibrillar polymer that is bound
to the ECM. Fibronectin forms dimers in which the 250-kD subunits are linked by a pair of
disulfide bonds. The ECM-fixed fibronectin is more effective in binding to integrins than the
soluble form. The ECM bound molecule is proposed to exist in an extended form that exposes its
integrin binding regions (Hynes 1999). Fibronectin can form a molecular bridge between the
bacteria and the α5β1 integrin molecules on the host cell (Ozeri, Rosenshine et al. 1998; Joh,
Wann et al. 1999; Cue, Southern et al. 2000). Integrins are heterodimeric receptors that mediate
cell adhesion, migration and tissue organization. They regulate the direct association of cells
with each other and with the ECM. Further, by binding to ligands, integrins provide a
transmembrane link for extracellular signals across the plasma membrane. This function is used
by several bacterial pathogens to, directly or via fibronectin, contact integrins and trigger a set of
conformational changes in the cell membrane that allows their internalization. Fibrinogen is a
340-kD plasma glycoprotein that forms a dimer. It plays an important role in the vascular system
by mediating platelet adherence and aggregation at injury sites. Fibrinogen can also interact with
a variety of ECM proteins and thus serves as a key factor in the matrix organization. Vitronectin,
a 75-kD glycoprotein, is present in both the blood and the ECM. Vitronectin also controls the
degradation of the ECM by stabilizing the plasminogen activator inhibitor-1. In addition,
vitronectin binds to some complement factors, heparin and to the thrombin-antithrombin III
complex. Thereby, it also participates in the regulation of clot formation. Laminin, is a massive
900-kD glycoprotein that serves as the major component of the basement membrane. Laminin is
involved in several important processes including cell attachment and proliferation, chemotaxis
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and angiogenesis. Elastin is highly flexible and therefore serves as the main constituent of the
ECM in organs that are required to expand and contract such as the lung, skin and large arteries.
Elastin consists of 36 domains with interlacing hydrophobic and cross-linking characteristics.
The rubber-like mechanical properties of elastin are derived from several repetitive hydrophobic
domains. These protein modules display an unstructured organization when elastin is in the
relaxed state and a structured organization when it is in the extended state. Finally,
glycosaminoglycans are a group of proteoglycans that consist of polysaccharide chains with a
protein core. They are present in the ECM of connective tissues as well as on the surface of
eukaryotic cells. Glycosaminoglycans function as coreceptors of cytokines and chemokines,
regulators of enzymatic activity and signaling molecules in response to injury or infection. Thus,
glycosaminoglycans are considered important for many cellular responses in development,
homeostasis and diseases (Trowbridge and Gallo 2002).

Adhesins in Gram-positive bacteria
Most Gram-positive pathogens encode multiple adhesins, which are typically expressed
according to different environmental cues representing the conditions that the bacterium may
confront during infection. The adhesins described below are categorized according to their
structure and host targets.

None-protein adhesins:
While most of the adhesins are proteins, both teichoic acid (TA) and polysaccharide capsules
mediate attachment in some Gram-positive organisms. TA, a main component of the cell
envelope in Gram-positive bacteria, is a glycerol phosphate polymer that can be bound to the cell
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wall or embedded in the outer leaflet of the cytoplasmic membrane. The negatively charged TA
associates with host cells through electrostatic attractions and weak hydrophobic interactions,
and therefore it allows bacteria to overcome the electrostatic repulsions found between bacteria
and mammalian cells. Some receptors of the innate immune system detect the presence of
bacteria by interacting with TA. The scavenger receptor A and CD36 on macrophages bind to
TA from Staphylococcus aureus (Greenberg, Fischer et al. 1996; Hoebe, Georgel et al. 2005). In
addition, the TA of S. aureus, Streptococcus agalactiae and Streptococcus pneumonia interacts
with the Toll-like receptor 2 of human macrophages and activate an innate immune response
(Schroder, Morath et al. 2003; Henneke, Morath et al. 2005).

An antiphagocytic capsule is produced by most of the pathogens that are capable of producing
systemic infections. The majority of capsules consist of polysaccharide polymers, although the
specific molecular components vary from organism to organism. Studies in multiple pathogens
have shown that the major role of the capsule is to enhance bacterial survival in the blood. The
capsule facilitates the escape from phagocytosis and reduces the complement activation on the
bacterial surface, which are both important defense mechanisms of the innate immune system.
For example, the sialic acid-modified capsule of S. agalactiae blocks C3b deposition on the
streptococcal surface and thereby prevents bacterial uptake by the phagocytic cells. A decrease in
capsule synthesis correlates with an increase in C3b deposition in S. agalactiae (Marques,
Kasper et al. 1992). The capsule in S. aureus contributes to abscess formation in rat model in a
mechanism that is independent of the capsule-mediated immune evasion (Tzianabos, Wang et al.
2001).
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Protein adhesins:
Protein adhesins are categorized into pili (otherwise known as fimbriae) and afimbrial-type based
on their structures. Pili are protein polymers made of a repeating subunit (major pilin) that forms
the backbone and one or more minor subunits that are typically located at the tip and facilitate
adherence (Scott and Zähner 2006). In some pili, however, adherence is mediated by the shaft
rather than the tip. Pili appear as filamentous structures, which typically extend 1 to 3 m from
the bacterial surface. Pilus synthesis is markedly different in Gram-negative and positive
organisms. In Gram-negatives, the pilus subunits are held together only by hydrogen bonds,
while in Gram-positive bacteria the pilus subunits are covalently linked to each other and the
pilus is bound to peptidoglycan. Biosynthesis begins with the export of the pilus subunits by the
general secretion pathway. At the surface, the subunits are then connected to each other by a
dedicated enzyme with a sortase-like function. The pilus grows from the tip, starting with the
minor subunits followed by the major subunits that create the shaft. Finally, each complete pilus
is anchored to the peptidoglycan by a sortase enzyme. This mechanism for pilus biosynthesis
substantially increases the strength of the pili structure in Gram-positive bacteria and makes it
difficult to dissociate from the surface. Pili are important for virulence of several Gram-positive
pathogens. In S. pneumonia for example, the genes required for pilus production are located in
the rlr pathogenicity islet, and the pili mediate pneumococcal adherence to lung epithelial cells
(Barocchi, Ries et al. 2006).

In addition to pili, Gram-positive bacteria also produce afimbrial adhesins, which are held at the
cell surface so that they can be available for interactions with the host. Afimbrial adhesins can be
covalently bound to the cell wall, embedded in the cell membrane, or noncovalently associated
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with other surface components. In general, cell wall-linked adhesins share the following
characteristics: an N-terminal signal peptide, a sortase recognition motif at the C-terminus (LPX
[T, S, A] G), followed by a hydrophobic transmembrane domain and a short positively-charged
tail. The signal peptide allows the protein export by the general secretion apparatus. The
hydrophobic segment and the positively-charged tail tether the C-terminus of the peptide in the
membrane, presenting it in the correct configuration to the sortase enzyme, which cleaves it at
the LPX site and links it to the peptidoglycan.

An important subfamily of afimbrial adhesins is called MSCRAMMs (microbial surface
components recognizing adhesive matrix molecules). These proteins target ECM components,
such as fibrinogen, fibronectin and collagen for adherence. Multiple MSCRAMMs have been
identified and characterized in important Gram-positive pathogens including S. aureus and GAS.
In addition to the cell-wall sorting signals described above, MSCRAMMs typically have a ligand
binding domain in their N-terminus. Several MSCRAMMs are pleiotropic and exhibit affinity to
other ligands and/or a catalytic activity in addition to ECM binding. ECM interactions are often
mediated by one or more repetitive sequences in the protein (Patti, Allen et al. 1994). A single
bacterium can express different MSCRAMMs that bind to the same ligand, while many
MSCRAMMs are capable of binding to more than just one ECM component. For example, both
of the S. aureus receptors, FnbpA and FnbpB, bind soluble and immobilized fibronectin.
Fibronectin then connects the bacterium to the host integrin α5β1, which in turn triggers the
uptake of S. aureus into the host epithelial and endothelial cells (Wann, Gurusiddappa et al.
2000; Schwarz-Linek, Hook et al. 2006). A third adhesin in staphylococcus, Map (or Eap),
recognizes a broad variety of ECM components, including fibrinogen, fibronectin,
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thrombospondin, vitronectin, bone sialoprotein, osteopontin and collagen. This protein that is
expressed in both a secreted and a cell-anchored form, mediates the attachment and
internalization of S. aureus into several types of eukaryotic cells. Map serves as an antiinflammatory protein as well as an adhesin. It binds directly to the host receptor ICAM-1 and
leads to attenuation of leukocyte recruitment (Chavakis, Hussain et al. 2002).

Afimbrial adhesins can target other host molecules in addition to the ECM components. For
example, the Staphylococcal adhesin Bbp, binds to the sialoprotein in osteoid (an organic portion
of the bone matrix). These interactions are important to the development of staphylococcal
osteomyelitis (Tung, Guss et al. 2000). Listeria monocytogenes is a Gram-positive food-borne
pathogen that can produce invasive infections. The major adhesins of L. monocytogenes,
internalin A and B, recognize the human E-cadherin and the hematocyte receptor, Met,
respectively. E-cadherin, a cell-cell cohesion molecule, is the suggested target of L.
monocytogenes at the gut epithelium, while Met is targeted by the pathogen during the invasive
stage of the disease (Lecuit, Ohayon et al. 1997).

Adhesins in Group A Streptococcus
GAS is a Gram-positive human pathogen. It commonly causes a variety of mild diseases,
including pharyngitis, impetigo, cellulitis and scarlet fever. Some episodes of GAS infections
lead to severe complications such as rheumatic fever, rheumatic heart disease and acute
glomerulenephritis. GAS can also produce systemic infections that involve the lungs, blood or
muscle. Acute GAS infections are rare (~1:100,000) but life-threatening, these include
necrotizing fasciitis (NF), myositis and streptococcal toxic shock syndrome (STSS)

11
(Cunningham 2000; Cunningham 2008). To ensure a successful colonization to a variety of sites
in the human body, GAS uses a spectrum of adhesins including TA, capsule, pili and a number
of MSCRAMMs. Hasty et al proposed a two-step model for the interaction of GAS with human
cells (Hasty, Ofek et al. 1992). The TA first mediates weak and reversible interactions with the
host, while other adhesins then direct the bacterial binding to other host ligands with high affinity.
The hyaluronic acid (HA) capsule of GAS allows binding to collagen fibers and to the
glycoprotein CD44 of human keratinocytes in vitro (Schrager, Alberti et al. 1998). However, the
in vivo role of the capsule in adherence is controversial. The capsule was found to mediate GAS
attachment in a study performed in a mouse skin infection model (Dinkla, Rohde et al. 2003),
while another study suggested that the GAS capsule masks important surface adhesins and thus
impairs adherence to human epithelial cells (Bartelt and Duncan 1978).

In 1933 Rebecca Lancefield established the classification of streptococci according to the
antigenic properties of the M protein and T antigen. Contemporary investigations, however,
established that both proteins partake in adherence; the M protein is afimbrial adhesin and the T
antigen is part of the pili. The M protein is the major virulence factor in GAS and it forms αhelical coiled coil dimmers, which have an extended shape and appear as hair-like projection on
the cell surface. The M protein is an antiphagocytic protein that is also involved in adherence.
The N-terminus of M protein is hypervariable and there are more than 200 M-protein based
serotypes and genotypes in GAS (Cole, Barnett et al. 2011). Different M proteins exhibit
binding to a combination of host plasma proteins, including the Fc portion of IgA and IgG, factor
H and fibrinogen. Binding to these host proteins protects GAS from opsonization. Some M
serotypes mediate GAS adherence to keratinocytes by binding to the membrane cofactor protein,
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CD46 (Okada, Liszewski et al. 1995; Giannakis, Jokiranta et al. 2002; Sandin, Carlsson et al.
2006). T antigen, also called protein T, is a trypsin-resistant surface protein that serves as the
major pilus subunit in GAS (Mora, Bensi et al. 2005). Studies done with the M1 strain SF370
demonstrated that bacterial adherence to human tonsil and primary skin cells is facilitated by the
pili (Abbot, Smith et al. 2007). In a separate investigation, the pili were found to bind the
salivary component gp340, leading to bacterial aggregation in saliva, which may facilitate
bacterial clearance during pharyngeal infection (Edwards, Manetti et al. 2008).

GAS expresses several adhesins that bind directly to host cells. These include the collagen-like
protein SclA, which carries a conserved collagen-like region and a hypervariable N-terminal
portion (Rasmussen, Eden et al. 2000). The collagen-like region mimics the function of human
collagens. It interacts with integrin α2β1 and activats intracellular signaling pathways in the host
cells (Humtsoe, Kim et al. 2005). Similar proteins with collagen-like sequences are found in a
wide range of bacteria, including S. pneumonia, Clostridium perfringens and Haemophilus
species. In addition, GAS produces multiple MSCRAMMs that bind to the ECM. Although
several adhesins that bind to collagen and laminin were found (Terao, Kawabata et al. 2002;
Kreikemeyer, Nakata et al. 2005), most of GAS MSCRAMMs bind to fibronectin (Talay 2005).

Fibronectin-binding adhesins in GAS
Fibronectin-binding adhesins are expressed by all streptococci. However, these receptors exhibit
significant variety in their binding characteristics, such as ligand affinity and preferences for the
soluble and/or the immobilized form of fibronectin. The typical fibronectin-binding receptors are
associated with the peptidoglycan, although some appear to lack a cell wall sorting motif. There
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are at least 11 fibronectin-binding proteins in GAS, including SfbI (aka PrtF1), protein F2
(PrtF2, aka FbaB and PFBP), SfbII (aka serum opacity factor, SOF) and FbaA (Kreikemeyer,
Klenk et al. 2004). Most of the MSCRAMMs that bind fibronectin have similar structural
organization and binding mechanism (Schwarz-Linek, Hook et al. 2006). The major fibronectinbinding activity is located to a tandem repeat (35-40 amino acid residues) region that is found at
the C-terminal half of the receptor (Fig. 2). The number of the repeats varies in different
adhesins, but the repeating units share significant homology with that found in various adhesins
of GAS and other Gram-positive bacteria. Some proteins also contain an upstream fibronectinbinding domain (UFBD). Several of the fibronectin receptors in GAS have additional functions.
For example, SOF and ScpA (aka C5a peptidase) have a lipoproteinase or a peptidase activity in
addition to fibronectin binding (Courtney, Hasty et al. 2003; Purushothaman, Park et al. 2004).
ScpA specifically inactivates the host complement factor, C5a, which inhibits the recruitment of
the polymorphonuclear neutrophils (Brown, Gu et al. 2005). Notably, the ScpA binds fibronectin
with high affinity through a unique mechanism that does not involve the common protein
repeats.
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Figure 2. The schematic illustration of fibronectin-binding repeats of SfbI.
Fibronectin binding repeats (FnBRs) target the N-terminal domain of Fn (NTD), which
comprises five Fn type 1 modules (1-5F1). (Figure adopted from Schwarz-Linek et al. 2006)
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Streptococcus pyogenes: Pathogenesis and epidemiology
Each year, over 10 million of noninvasive GAS diseases, primarily throat and superficial skin
infections occur worldwide. In addition, GAS causes an array of invasive diseases, due to which
a massive cost is spent every year. The severe GAS diseases appear in the U.S. at a rate of about
3.6/100,000 in population, producing significant morbidity. In 2009 for example, 11,000
invasive infection cases were reported, leading to 1,300 deaths. (Centers for Disease Control and
Prevention. 2010. Active Bacterial Core Surveillance Report, Emerging Infections Program
Network, group A Streptococcus, 2009). Therapies with penicillin and clindamycin are the most
effective ways to treat noninvasive streptococcal infections. However, while treatment with
antibiotics may prevent the development of invasive GAS diseases, antibiotics are not an
effective treatment at the systemic stage (Young, Aronoff et al. 2005; Cole, Barnett et al. 2011).
For patients with necrotizing fasciitis for example, early surgery is required to remove damaged
tissues and to prevent the spread of bacteria within the body. The mortality rate of this disease is
usually higher than 50% because of the multiple organ failure.

Development of recent vaccines against streptococcal diseases
There is still no method available to prevent GAS infections and to effectively treat invasive
GAS episodes (Steer, Batzloff et al. 2009). These challenges underscore the needs for a GAS
vaccine. Multiple vaccine candidates have been investigated in the past fifty years, including Mprotein and other antigens. Immunization with M protein provides protection from clinical
strains. However, M1 protein, the most prevalent serotype in invasive cases, is a potent inducer
of T-cell proliferation and therefore leads to strong release of Th1-type cytokines. Thus,
vaccination with M1 and possibly with other M serotypes suffers from the serious concern that it
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may lead to excessive T-cell activation and harmful inflammatory responses (Påhlman, Olin et
al. 2008). Moreover, some M serotypes, such as M18 are implicated in the production of the post
streptococcal sequelae, acute rheumatic fever, which can lead to a rheumatic heart disease
(Smoot, Barbian et al. 2002). It is suggested that rheumatic M types share antigenic epitope with
host components and as a result trigger autoimmune response with severe inflammatory disease.
Streptococcal autoimmune complications can lead to lasting damage to the joins and the heart
and are suggested to be the cause of several neurological disorders (Snider and Swedo 2003). A
26-valent vaccine that is based on the variable N-terminus of M was recently developed. This
vaccine that excludes previously identified cross reactive epitopes was found protective and safe
in phase I and II clinical trials (Shulman, Tanz et al. 2009). However, a significant concern raised
by M-based vaccines is the wide variety (over 200) of the different M serotypes, since the
spectrum and prevalence of the M types are likely to change over time, especially in response to
the pressure imposed by immunization with selected serotypes. A vaccine candidate that is based
on an antigen that is conserved among GAS strains would be more attractive. Several GAS
surface components and virulence factors have been tested for their ability to elicit immunity.
These include the ScpA, GAS surface carbohydrates, several fibronectin-binding proteins,
exotoxins and pili. While some antigens were protective against one or more GAS strains, none
of them has reached clinical trials.

The streptococcal hemoprotein receptor (Shr)
The Shr protein is encoded by the first gene of streptococcal iron acquisition (sia) operon and its
expression is regulated by iron via the metal-dependent repressor, MtsR (Bates, Toukoki et al.
2005; Toukoki, Gold et al. 2010). Shr is able to acquire heme from the environment and various
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host hemoproteins. Shr ligands include hemoglobin, myoglobin, heme-albumin and hemoglobinhaptoglobin (Bates, Montanez et al. 2003; Ouattara, Bentley Cunha et al. 2010).

Shr harbors a leader peptide, two DUF1533 domains (domain of unknown function) two hemebinding NEAT (NEAr Transporter) domains that are separated by a leucine rich repeat (LRR)
region. A short hydrophobic segment is located at the C-terminus of Shr. The DUF1533 domain
is 60 amino acids long and it is typically found in several copies in bacterial proteins from
several species of Clostridium, Streptococcus and a few related bacteria. The InterPro protein
domain database suggests that many of the proteins that harbor one or more DUF1533 domains
also contain a LRR region. This suggests that these domains cooperate for some functions. The
NEAT domain is about 125 residues and is often found in multiple copies in secreted or surface
exposed proteins in Gram-positive organisms. All of the characterized NEAT domains bind
heme and/or hemoproteins. Most of the bacterial species producing NEAT proteins are important
human pathogens, these include Bacillus anthracis, L. monocytogenes, Clostridium perfringens,
S. aureus and GAS (Andrade, Ciccarelli et al. 2002). LRR regions typically contain repeats of
20-29 amino acid segments that are rich with leucine. They are mostly found in eukaryotic
proteins with diverse functions and cellular locations. This LRR domain is suggested to mediate
protein-protein interactions (Kobe and Kajava 2001). For instance the LRR domain of Internalin
A interacts with E-cadherin and is sufficient for internalization of L. monocytogenes into
epithelial cells (Lecuit, Ohayon et al. 1997; Schubert and Heinz 2003).

In this dissertation, we investigate the importance of Shr for GAS pathogenesis and study its
promise as a vaccine target for GAS and related pathogens.
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CHAPTER I
SHR IS A BROAD-SPECTRUM SURFACE RECEPTOR THAT CONTRIBUTES TO
ADHERENCE AND VIRULENCE IN GAS

INTRODUCTION
The group A Streptococcus (GAS), also known as Streptococcus pyogenes, is a versatile human
pathogen that colonizes the mucosal surfaces of the upper respiratory pathways and the
epidermis (Cunningham 2000).

GAS usually produces self-limited infections such as

pharyngitis, impetigo and erysipelas. Infrequently, GAS also causes severe invasive infections
in a variety of body sites, including bacteremia, necrotizing fasciitis and myositis. In addition to
the immediate damage caused by primary GAS infections, some episodes lead to the
development of Streptococcal Toxic Shock Syndrome (STSS) or to autoimmune complications
such as glomerulonephritis and acute rheumatic fever, resulting in renal injury or inflammation
of connective tissue respectively. Acute rheumatic fever can trigger additional manifestations in
the form of rheumatic heart disease and the neurological syndrome Sydenham's Chorea (Snider
and Swedo 2003). The wide spectrum of GAS-related illnesses makes it an intriguing pathogen
and underscores the complexity of GAS interactions with the human tissues and immune
response.

The initial, non-specific interaction of GAS with the host tissues is provided by lipotechoic acid
(LTA). This amphipathic surface molecule is proposed to counteract the electrostatic repulsion
between the bacteria and the host surfaces. The subsequent step in adherence involves high-
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affinity binding to host components and is mediated by a large number of adhesins (Bisno, Brito
et al. 2003; Kreikemeyer, Klenk et al. 2004; Talay 2005). These include M proteins from several
serotypes, F and F-like proteins, hyaluronic acid (HA) capsule and the recently described pili
(Abbot, Smith et al. 2007; Manetti, Zingaretti et al. 2007). Some of the adhesins in GAS bind
directly to molecules on the host cell surface. For example, M6 and the HA capsule bind to the
keratinocyte receptors CD46 and CD44 respectively (Okada, Liszewski et al. 1995; Schrager,
Alberti et al. 1998; Giannakis, Jokiranta et al. 2002), and the GAS collagen-like protein, Scl1,
interacts with the 21 integrin expressed by human epithelial cells (Caswell, Lukomska et al.
2007). More often, GAS adhesins attach the bacterium to the extracellular matrix (ECM) or to
plasma components that in turn function as a bridge between the bacterium and receptors on the
host cells. This mechanism of bacterial attachment is very common among pathogenic Grampositive cocci and the bacterial proteins involved are called MSCRAMMs (Microbial Surface
Components Recognizing Adhesive Matrix Molecules) (Patti, Allen et al. 1994). GAS expresses
several surface molecules that bind collagen or laminin (Elsner, Kreikemeyer et al. 2002; Terao,
Kawabata et al. 2002; Dinkla, Rohde et al. 2003; Kreikemeyer, Nakata et al. 2005). However,
many more GAS adhesins target the ECM component fibronectin (Kreikemeyer, Klenk et al.
2004; Talay 2005). At least 11 fibronectin-binding proteins were identified in GAS thus far,
including F1 (SfbI), F2 (PFBP), Fbp54, SOF, and several M proteins. While a few of these GAS
proteins (such as Fbp54) are ubiquitous and encoded by most serotypes, others are found only in
some or even in a single serotype. Moreover, most of the fibronectin-binding proteins in GAS
are individually regulated and are expressed under unique growth conditions or in response to
certain environmental stimuli (Kreikemeyer, McIver et al. 2003; Kreikemeyer, Klenk et al.
2004).

20
The production of infection by GAS and its survival in the host environment is dependent on its
ability to acquire essential nutrients such as iron. GAS growth in vitro in iron-restricted medium
is supported by whole blood, serum, myoglobin, hemoglobin, and hemoglobin-haptoglobin
complex, but not by the ferric-carrier proteins transferrin and lactoferrin (Francis, Booth et al.
1985; Eichenbaum, Muller et al. 1996; Podbielski, Woischnik et al. 1999). Hence, heme, the
most abundant iron form in mammals, serves as a major source of iron for this hemolytic
pathogen.

The sia is an iron-regulated operon in GAS involved in heme acquisition and

transport. In addition to five genes with unknown function, the sia codes for shr, shp, and the
siaABC (htsABC) genes (Lei, Smoot et al. 2002; Bates, Montanez et al. 2003). The SiaABC
proteins are the components of an ABC type heme-transporter. Shp is a surface protein that was
shown to acquire heme from hemoglobin and transfer it to apoSiaA (HtsA) while forming a
stable complex with it (Liu and Lei 2005). Shr, encoded by the first gene in the sia operon, is a
145 kDa protein which binds myoglobin, hemoglobin, and hemoglobin-haptoglobin complexes
(Bates, Montanez et al. 2003). Two NEAT (NEAr Transporter) domains are found in Shr (Fig.
2A) (Andrade, Ciccarelli et al. 2002). While their functional role is not well understood, NEAT
domains appear to share a common immunoglobulin-like fold, and some of them were found to
bind heme (Mazmanian, Skaar et al. 2003; Newton, Klebba et al. 2005; Maresso, Chapa et al.
2006; Grigg, Vermeiren et al. 2007) and/or heme-containing proteins (Mazmanian, Skaar et al.
2003; Clarke, Wiltshire et al. 2004; Torres, Pishchany et al. 2006; Dryla, Hoffmann et al. 2007).
In this study, we explored Shr’s function and investigated its contribution to GAS pathogenesis.
We demonstrate here that in addition to its likely role in heme acquisition, Shr is a MSCRAMM
that specifically binds to fibronectin and laminin, and mediates bacterial attachment. We report
that Shr is expressed in vivo and is important for GAS virulence in a zebrafish infection model.
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MATERIALS AND METHODS

Bacterial strains and growth conditions. The E. coli strains DH5and Top10 (Invitrogen)
were used for cloning and gene expression. The clinical GAS (S. pyogenes) isolates used in this
study were obtained from the Georgia Emerging Infections Program (GEIP) and are listed in
Table 1. The other GAS strains used in this study were MGAS5005, an M type 1 strain (Sumby,
Porcella et al. 2005); JRS6, an M type 6 strain (Scott, Guenthner et al. 1986); NZ131, an M type
49 strain (Simon and Ferretti 1991); ZE4912, a shr mutant constructed in NZ131 (Provided by
Dr. Bernard Beall, Centers for Disease Control and Prevention, Respiratory Diseases Branch,
Atlanta, GA. Fig 3). The shr mutation in ZE4912 is a deletion-insertion mutation made by
replacing an internal 0.3-kb BglII fragment with the spectinomycin resistance gene, aad9
(personal communication, Dr. Bernard Beall). We confirmed the structure of the shr mutation in
ZE4912 genome, by sequence analysis of a DNA fragment carrying the mutant shr allele
amplified from ZE4912 chromosome, with ZE245 (5’-GTGCCCACAAAACCAAGGCACAC3’) and ZE246 (5’-CAGTCGATGAGTATCGGCGAG-3’) primers.

The Lactococcus lactis

strain MG1363, was used as a heterologous host for the expression of the native Shr protein from
plasmid pXL14. E. coli cells were grown in Luria-Bertani broth with agitation. GAS was grown
statically in Todd-Hewitt broth with 0.2% w/v yeast extract (THY, Difco Laboratories). L. lactis
was grown statically at 30°C, in M17 (Difco Laboratories) supplemented with 0.5% w/v glucose.
When necessary, spectinomycin at 100g/ml or kanamycin at 70g/ml was added to the
medium.
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Nucleic acid methods.

Chromosomal and plasmid DNA extraction, DNA manipulations

including restriction digests, cloning, and DNA transformation into E. coli, GAS, or L. lactis
were done according to the manufacturer’s recommendations and with standard protocols as
previously described (Sambrook 1989; Eichenbaum, Federle et al. 1998). For RNA extraction
and analysis, GAS cells were harvested at the logarithmic growth phase and total RNA was
prepared

using

the

RiboPure-Bacteria

Kit

(Ambion).

RNA

was

quantified

spectrophotometrically, and its integrity was examined by agarose gel electrophoresis. The
absence of DNA contamination was verified by PCR. cDNA was produced by Superscript III
reverse transcriptase (Invitrogen) according to the manufacturer’s specification.

One

microgramof RNA was used in the reverse transcription step, and 1/20 of the reaction served as
a template for 25 cycles of PCR. The primers SRAR (5’-CTGATGCTACTGCCATAGCAG-3’)
and SRAL (5’-GCGTTCAGGAGGTCTAGCTC-3’) were used in the analysis of the recA gene
and the primers 204A-Fwd (5’-GCTATGATGCTGTTAAGCGTGTGG-3’) and 204A-Rev (5’TCTGGAATGGCATGAGCTGTTC-3’) were used in the analysis of siaA transcription.

Construction of the shr complemented strain ZE4924. To complement the shr mutation in
ZE4912 we cloned the native shr gene into the temperature sensitive plasmid pJRS700
(Montanez, Neely et al. 2005). A 4.5-kb fragment amplified from NZ131 chromosome with the
primers ZE170 (5’-TTTTTTATCGATTTAGCTCTTGCTGACTAG-3’) and ZE174 (5’TTTTTTATCGATTATGCAGTAGTGACATCTC-3’) was cloned into the ClaI site of pJRS700
generating plasmid pXL14. Since ZE4912 cells harboring pXL14 did not grow well at 30ºC
(possibly due to the high gene dosage of shr carried by pXL14), we constructed a merodiploid
strain (ZE4924), which contains both the mutant and the wild type alleles of shr in the
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chromosome. The strain ZE4924 was made in ZE4912 by Campbell insertion. Plasmid pXL14
was introduced into ZE4912 cells. Clones in which pXL14 was integrated into the chromosome
(by homologous recombination between the mutant shr allele in the chromosome and the wild
type copy on pXL14) were selected on kanamycin plates at 37ºC (the non-permissive
temperature). The resulting chromosomal structure was verified by PCR analysis.

Antibodies. Rabbit polyclonal antibodies against Shr and rabbit anti-SiaA serum have been
previously described (Bates, Montanez et al. 2003). Rabbit polyclonal antibodies against M
protein type 49 (a killed whole-cell vaccine that was absorbed extensively to produce M49
specific antiserum) were provided by Dr. Bernard Beall (Centers for Disease Control and
Prevention, Respiratory Diseases Branch, Atlanta, GA). Rabbit IgG against GAS type-specific
carbohydrates was purchased from Abcam, Inc. Rabbit antiserum for the metal dependent
repressor MtsR (Bates, Toukoki et al. 2005) was raised against purified MtsR using the same
method employed for the production the Shr antiserum (Bates, Montanez et al. 2003). Western
blot analysis determined that the MtsR antiserum specifically recognize purified MtsR protein
and reacted with protein band at the correct size in protein extract from the wild type NZ131
strain but not from the mtsR mutant ZE491 (Fig. 3). Mouse antiserum against Lactococcus lactis
surface components was raised by intraperitoneal injection with 108 CFU of MG1363 cells. A
booster injection was given 10 days after the first injection. Antiserum was collected 10 days
after the booster.
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Figure 3. MtsR antiserum specifically recognizes MtsR protein.
Equal amount of total cell lysate of GAS NZ131 (wild type), ZE4912 (shr-) and ZE491(mtsR-)
were analyzed by SDS-PAGE, followed by Western blot with rabbit anti-MtsR. Purified MtsR
protein is the positive control.
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Preparation of GAS cell fractions. GAS cell fractionation was done as previously described
with minor modifications (Pancholi and Fischetti 1992). Essentially, GAS was grown overnight
in THY broth containing 20 mM glycine. Cells from 14 ml cultures at O.D600 = 1.0 were
harvested, washed with phosphate buffered saline (PBS), and resuspended in 0.5 ml of either
TEA (10 mM Tris-HCl buffer pH 8.0, 1 mM EDTA, and 0.75 g/l of the protease inhibitor
AEBSF, Roche) for the preparation of total cellular proteins, or in TEAR (TEA with 30%
raffinose) for cellular fractionation.

The cell suspensions were treated with the muralytic

enzyme mutanolysin (500U) for 1 h at 37ºC to dissolve the cell wall. For total protein extract,
the mutanolysin treated cells were boiled in sample buffer for 10 min. For cell fractionation, the
protoplasts were separated from the cell surface fraction by centrifugation, resuspended in TEA,
and lysed by successive cycles of freezing (-80ºC) and thawing (37ºC). Membrane proteins were
separated from the soluble intracellular proteins by centrifugation and were dissolved by boiling
in sample buffer. The protein extracts were standardized with respect to the cell number in the
corresponding culture, and were separated on a 10% sodium dodecyl sulfatepolyacrylamide gel
electrophoresis (SDS-PAGE). Shr, M protein type 49 (M49), or SiaA were detected by Western
blot as described previously (Bates, Montanez et al. 2003).

Purification of rShr (His6-Xpress-Shr). The recombinant Shr was purified from the E. coli
cells harboring plasmid pCB1 as previously described (Bates, Montanez et al. 2003) with the
following modifications: the cells were resuspended in 20 mM Tris pH 8.0, 100 mM NaCl, 0.1%
Triton X-100, 0.5 mg/ml lysozyme, and a protease inhibitor cocktail (Complete Mini, EDTAfree, Roche), and incubated on ice for 30 min. The bacteria were then lysed by sonication, and
the rShr was purified over a nickel column (HisTrap HP, GE Healthcare) and subsequently

26
desalted by HiTrap Desalting column (GE Healthcare). The purified protein was examined by
SDS-PAGE and Western blot analysis with anti-Shr antibodies, and quantified by the Bradford
assay (Bio-Rad).

Enzyme-linked Immunosorbant assays (ELISA). Three types of ELISA assay were used in
the binding experiments. ELISA with immobilized bacteria. This assay was preformed to study
the availability of Shr on the bacterial cell surface. GAS or L. lactis cells from overnight
cultures were harvested, washed with phosphate buffered saline (PBS), and used to coat 96-well
EIA/RIA microplates (Costar, Corning Inc.) overnight at 4ºC.

The supernatant was then

aspirated and the plates were washed with PBST (PBS containing 0.05% Tween 20). After
blocking with PBST and 5% skim milk for 1 h at 37ºC, the wells were washed with PBST and
incubated with the primary antibody for 1h at 37ºC. The microplates were next washed with
PBST and incubated with secondary antibodies conjugated to alkaline phosphatase (AP) for 1h at
37ºC.

The reaction was developed using p-nitrophenyl phosphate system (KPN) and the

absorbance was read at 405 nm. Elisa with immobilized ligands and purified Shr protein. This
assay was used to investigate binding of Shr to host proteins. The microplates were coated with
the ligands (25g/ml), washed, and blocked as described above. Purified Shr (in PBST-1%
BSA) was added to the coated wells in increasing concentrations. After 1 h incubation at 37 ºC,
Shr antiserum (diluted in PBST-1% BSA) was added to the wells, and the plates were incubated
for 1 h at 37 ºC. The wells were then washed with PBST, and binding was detected with APconjugated secondary antibody as described above.
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Analysis of L. lactis cell binding to immobilized ligands by ELISA. The microplates were
coated with the ligands (25g/ml), washed, and blocked as described above. Samples of L. lactis
cultures were harvested, washed with equal volume of PBS, diluted into the desired
concentrations in PBST-1% BSA, and applied to the wells. Following 1 h incubation at 37 ºC,
the plates were washed with PBST, and reacted with the L. lactis antiserum. Binding was
detected with secondary AP-conjugated antibody as described above.

Detection of anti-Shr antibodies in convalescent mice. Mice were injected subcutaneously
with 2x107 CFU of the wild-type strain MGAS5005 as previously described (Schrager,
Rheinwald et al. 1996) and were monitored for 27 days.

The infected mice developed

subcutaneous lesions, which healed over time in the surviving animals (~80% of the injected
mice). On the 28th day post inoculation, the surviving mice were bled by cardiac punctuation and
the serum was obtained by centrifugation. ELISA assay was used to determine the presence and
the titer of anti Shr antibodies in the mice sera. 96-well EIA/RIA microplates (Costar, Corning
Inc.) were coated with 1g/ml purified Shr. Following overnight coating at 4ºC, the plates were
washed with PBST (PBS containing 0.05% v/v Tween 20), and blocked with 1% w/v BSA in
PBST for 1 h at 37ºC. The plates were then washed with PBST and incubated for 1h at 37ºC
with mouse sera at different dilutions. Following incubation and washing, AP-conjugated antimouse antibodies diluted 1:1000 in blocking buffer, was added to the plates and incubated for 1h
at 37ºC. Bound antibodies were detected by using p-nitrophenyl phosphate system (KPN). Plate
contents were incubated at room temperature for 30 min and read at 405 nm.
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HEp-2 cell culture and adherence assay. HEp-2 cells were cultured in 24-well tissue culture
plates with nutrient mixture medium (RPMI) supplemented with 10% fetal bovine serum at 37ºC
in an atmosphere with 5% CO2. For adherence assays, cells grown to a semi confluent state
(~105 cells/well) with antibiotics (2% Penicillin-Streptomycin, Thermo Scientific Hyclon
Antibiotics) were washed with PBS and inoculated with GAS cells (107 CFU/well) harvested at
the mid-log phase (OD600 = 0.3-0.4), washed with PBS, and resuspended in RPMI medium. The
bacteria were incubated with the tissue cultures for 2 h at 37 ºC; at that time, non-adherent
bacteria were removed by successive washes with PBS. To determine the number of adherent
bacteria, the HEp-2 cells were detached with 100l of 0.05% trypsin for 5 min at 37 ºC and lysed
with 400l per well of 0.025% Triton X-100. The bacterial number in each sample was
determined by plating on THY agar plates. Each adherence experiment was performed in
triplicate or quadruplicate.

Zebrafish care and virulence assays. Care and feeding of zebrafish (Danio rerio) followed
published methods (Westerfield 1995; Neely, Pfeifer et al. 2002). Streptococci were cultured
overnight in THY with 2% (w/v) peptone (THYP) at 37 ºC, diluted 1:100 in THYP the next day,
and incubated at 37ºC. The cells were harvested at OD600 = 0.3, washed once with THYP, and
diluted to an appropriate concentration in fresh THYP.

Streptococcal cells (10l) were

aseptically injected into groups of six anaesthetized male breeder zebrafish (Scientific
Hatcheries). Following intramuscular (i.m.) infection, the fish were allowed to recover in 225 ml
sterilized ddH2O supplemented with aquarium salts (Instant Ocean; Aquarium Systems) at a
concentration of 60 mg/l in a 25 ºC incubator. Infected fish were monitored for 72 h and death
was recorded in intervals of 12 h. The 50% lethal dose (LD50) for infection was determined by
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Reed-Muench method as previously described (Neely, Pfeifer et al. 2002) where zebrafish were
challenged over a range of 103-107 CFU of each of the streptococcal strains.

Competitive assay in zebrafish model. The competitive index was defined as the change in the
population ratio of two strains after growing in zebrafish muscle. NZ131 (wild type) and the
mutant strain (ZE4912) were cultured separately as described above. Cells from each strain were
mixed in a 1:1 ratio to a final concentration 108 CFU/ml. Zebrafish were infected i.m. with 10l
of this mixture, resulting in an infectious dose of 106 CFU. After 24 h, muscle lesions were
collected from euthanized fish and homogenized in PBS. The homogenates were plated on THY
and THY-spectinomycin plates, and the ratio of mutant to wild type strain in the lesion was
determined.

Statistical analysis. Student’s t-test was used to compare data sets derived from two groups to
each other; a P-value ≤ 0.05 was considered significant. ANOVA analysis followed by the
Tukey’s HSD post hoc test were used for multigroup comparisons; a P-value ≤ 0.05 was
considered significant.

Zebrafish survival data were analyzed by the method of Reed and

Muench for the calculation of the LD50. Kaplan-Meier plots of zebrafish survival were used to
compare infection by the wild type, mutant and complemented GAS strains. The statistical
significance was evaluated by the log rank test (Glantz 2005).
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RESULTS

Shr is attached to the GAS cell membrane and is exposed to the extracellular environment.
Shr is a large (1,275 amino acids) protein found in both the culture supernatant and in association
with whole cells (Bates, Montanez et al. 2003). It has a functional leader peptide, and at its
carboxy terminus it has a putative transmembrane domain followed by a positively charged tail
(Fig. 4A). However, unlike proteins anchored to the surface of Gram-positive bacteria, Shr lacks
a cell wall anchoring motif at its C terminus (Scott and Barnett 2006) suggesting that after it is
exported to the cell surface, Shr may be bound to the cell membrane and not anchored to the cell
wall. To determine the cellular location of Shr, GAS strain NZ131 (M type 49) was fractionated
following digestion with the muralytic enzyme mutanolysin and examined by Western blot
analysis. The Shr protein (at 145 kD) was not released by this process but was found instead in
the membrane fraction (Fig. 4B). As a control, the cell wall protein M49, represented by the
monomer at 37-40 kD (as predicted from the genome sequence) and the typical range of slowermigrating bands containing cell wall fragments (Fischetti, Jones et al. 1985) was found
exclusively in the cell wall fraction, as expected (Fig. 4C). Therefore, Shr appears to remain
associated with the cell membrane, probably by the transmembrane domain in its carboxy
terminus.
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Figure 4. Shr protein domains and cellular location.
(A) Schematic representation of Shr protein. The SMART algorithm (http://smart.emblheidelberg.de) was used for structural analysis of Shr. The location of protein domains
(expressed as amino acid number) is shown. LP, leader peptide; NEAT 1, NEAT domain 1;
LRR, Leucine rich repeats; NEAT 2, NEAT domain 2; TM, transmembrane domain. (B and C)
Proteins prepared from NZ131 cells grown in THYB were analyzed by Western blotting using
anti-Shr antibodies (B) or anti-M49 antibodies (C). T, total protein; CW, cell wall fraction; CM,
cell membrane fraction. Full length Shr and M49 are indicated by the arrows.
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The cellular location of Shr was further studied in an shr deletion-insertion mutant (ZE4912, Fig.
5A) and the mutant strain complemented with shr expressed from its own promoter in the
chromosome (ZE4924, Materials and Methods). To examine the effect of shr mutation and of its
complementation on the expression from the sia operon, we preformed RT-PCR and Western
blot analysis on RNA and proteins extracted from the isogenic strains NZ131, ZE4912, and
ZE4924. As can be seen in Fig. 5, the transcription of siaA gene (Fig. 5B) and the production of
this protein (Fig. 5C) were not significantly altered in either the mutant or in the
complementation strain in comparison to the parent strain. Therefore, the mutation in shr does
not seem to be polar on the downstream genes in the sia operon. On the other hand, cell
fractionation and Western blot analysis showed that the shr mutation in ZE4912 resulted in the
loss of Shr from the membrane fraction (Fig. 5D, panel 2) and in the formation of a truncated Shr
fragment (25-kDa) that was secreted to the culture supernatant (data not shown).
Complementation of shr in ZE4924 strain restored the presence of Shr protein in the cell
membrane fraction (Fig. 5D, panel 3). These observations are consistent with the suggestion that
the carboxy terminus of Shr is required for Shr association with the cell membrane, and with our
previous observation that Shr has a leader peptide that can target its secretion.

33

Figure 5. Successful inactivation of shr in strain ZE4912 and mutant complementation in
strain ZE4924.
(A) Schematic representation of the sia operon and the shr mutation in ZE4912. The shr
mutation in strain ZE4912, consists of a small deletion and an insertion of the spectinimycin
resistance gene aad9. ZE4924 strain is a merodiploid, which carries both the mutant and the
wild type alleles of shr in the chromosome (see Materials and Methods). (B to D) RNA and
proteins from the wild type NZ131 (1); the shr mutant ZE4912 (2); and the shr complemented
strain ZE4924 (3) were prepared and analyzed. (B) Total RNA was extracted, loaded (1 g/well)
on agaros gel, and examined for integrity. Reverse transcription-PCR products obtained with
recA specific primers (used to control for equal amounts of RNA template) or with siaA-specific
primers were analyzed by agarose gel electrophoresis. (C) Total proteins were prepared, and
analysed by Western blot with anti-SiaA serum. (D) Proteins from the membrane fraction were
analyzed by Western blotting with anti-Shr serum. Full length Shr is indicated by the arrow.
(work (B) and (C) were performed by X. Li (Fisher, Huang et al. 2008)).
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To test whether the membrane-bound Shr is exposed on the cell exterior or is buried within the
peptidoglycan layer, we conducted whole-cell ELISA using Shr antibodies. GAS cells grown to
stationary phase were used to coat ELISA plates and reacted with anti-Shr serum. An antiserum
against the repressor protein MtsR (Bates, Toukoki et al. 2005) was used as a control for
intracellular proteins, and normal rabbit serum (NRS) was used as a control for any non-specific
reaction. As shown in Fig. 6, the Shr antiserum (black bars) reacted with the wild type (NZ131)
and with the complementation strain (ZE4924). The specificity of the antiserum for Shr was
demonstrated by its lack of reaction with shr mutant strain (ZE4912). In all tested strains, no
significant reactivity was obtained with the MtsR antiserum or the NRS (stripes and white bars
respectively). As expected, the positive control antibodies, which specifically recognize GAS
type-specific carbohydrates, reacted with all of the GAS strains examined (gray bars). Similarly
to its interaction with NZ131 whole cells, Shr antiserum specifically recognized cells of JRS4 (M
type 6) and MGAS5005 (M type 1) strains (data not shown). These observations suggest that
Shr is exposed on the surface and accessible for interactions with the host extracellular
environment.
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Figure 6. Shr is exposed on the surface of GAS.
Data are from ELISA with GAS cells immobilized onto microtiter plates. Wells coated with
cells from the isogenic series NZ131, ZE4912, and ZE4924, were reacted with antibodies
recognizing GAS type-specific carbohydrates (gray bar), Shr antiserum (black bar), or control
antibodies MtsR antiserum (strips bar) or normal rabbit serum (white bar) as described in
Materials and Methods. Antibody binding to GAS surface antigens was detected by anti-rabbit
AP-conjugated secondary antibodies. The reaction was developed and measured at 405 nm.
Each bar represents the average of at least three repeats, and the standard deviation (SD) is
represented by the error bars. The significance of the difference in binding of anti-Shr serum to
the three strains was examined by ANOVA (P = 0.001), followed by the Tukey’s HSD test for
each strain pair. The asterisk indicates that the difference between the strains is significant (P <
0.01 for each strain pair).
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Shr is an MSCRAMM. The surface localization and exposure of Shr raised the possibility that
it may function in bacterial adherence in addition to iron uptake. We therefore examined the
interactions of Shr with ECM components, using ELISA assays. Different ligands immobilized
onto microtiter plates were reacted with increasing concentrations of purified Shr. Shr binding
was detected using Shr antiserum (Fig. 7). As control for non-specific interactions, wells coated
with transferrin, fibronectin, laminin, or goat IgG, were incubated with the Shr antiserum
directly. Only low background binding (OD405 = 0.1 ± 0.01, Fig. 7, and data not shown) of the
Shr antiserum to the control wells was observed demonstrating the specificity of the Shr
antibodies. Although Shr did not bind to transferrin (Fig. 7, diamonds) and goat IgG (data not
shown), Shr bound to immobilized fibronectin (Fig. 7, triangles) and laminin (Fig. 7, squares) in
a dose-dependent and saturable manner.

Inhibition experiments demonstrated the specificity of binding of Shr to the ECM ligands
fibronectin and laminin. When Shr was allowed to interact with immobilized fibronectin in the
presence of increasing concentrations of soluble fibronectin, binding of Shr to the plates was
inhibited in a dose dependent manner (Fig. 8A, triangles). On the other hand, transferrin, which
was not recognized by Shr in vitro, could not compete with immobilized fibronectin for binding
to Shr (Fig.8A diamonds). Similarly, soluble laminin inhibited binding of Shr to wells coated
with laminin (Fig. 8B). Laminin also competed with fibronectin for Shr binding (up to 40%
inhibition, Fig. 8A, squares).

However, at similar molar concentrations, laminin was less

effective at competition than was soluble fibronectin (80% inhibition). This demonstrates that
binding of Shr is specific to a subset of ECM components.
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Figure 7. Shr binds in vitro to ECM components.
The Shr protein was added in increasing concentrations to microtiter plate wells coated with
fibronectin (triangles), laminin (squares), or transferrin (diamonds) and incubated for 1 hour at
37C. Bound Shr was detected by anti-Shr antibodies and anti-rabbit AP-conjugated secondary
antibodies. Each datum point stands for the mean ± SD (represented by the error bar) from four
independent experiments done in duplicates.
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Figure 8. Inhibition of Shr binding to immobilized ECM ligands.
(A) Binding of purified Shr to immobilized fibronectin as a function of the competitor
concentration. Shr (3.5 nM) was pre-incubated for 1.5 h at room temperature with increasing
concentrations of fibronectin (triangles), laminin, (squares), or transferrin (diamonds) prior to its
addition to fibronectin-coated wells. Bound Shr was detected with anti-Shr and anti-rabbit APconjugated secondary antibodies. (B) Binding of Shr to immobilized laminin as a function of
soluble laminin concentration. Data are the same as in A except that 3.5 nM of Shr was preincubated with increasing concentrations of laminin before incubation in the laminin-coated
wells. In both A and B, each datum point represents the mean of six independent experiments
done in duplicate, and the standard deviation is represented by the error bars. The competitor
amount is expressed as a multiple of the molar concentration Shr.
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GAS expresses multiple fibronectin binding proteins on its surface (Kreikemeyer, Klenk et al.
2004; Talay 2005). To test the ability of Shr to mediate bacterial binding to fibronectin in the
absence of the other GAS fibronectin-binding proteins, we expressed Shr in a heterologous host.
Plasmid pXL14, which carries the native shr gene, was introduced into L. lactis MG1363 strain.
The production of Shr protein in Lactococcus was confirmed by Western blot analysis (data not
shown), and the presentation of Shr on the cell surface was tested by ELISA. Microtiter plates
were coated with cells of the native L. lactis strain MG1363 or the recombinant strain that
harbors pXL14 (MG1363/pXL14). The coated wells were reacted with Shr antiserum (Fig. 9A,
black bars), L. lactis antibodies (Fig. 9A, gray bars), or NRS (Fig. 9A, white bars). The Shr
antiserum reacted significantly (P = 0.0037) only with the bacteria that harbor the shr plasmid
(pXL14), demonstrating specificity for Shr. As expected, the L. lactis antibodies interacted
strongly and similarly with both MG1363 and MG1363/pXL14 strains, and only weak binding of
the NRS to both strains was observed. Therefore, like in its native host, Shr protein produced in
L. lactis is exposed on the bacterial cell surface.

Binding of the recombinant L. lactis cells expressing Shr to fibronectin and to transferrin was
investigated. The two ligands were immobilized onto microtiter plates and the coated wells were
incubated with bacteria. Binding of Lactococcus to the immobilized ligands was detected using
the L. lactis antiserum. Only weak binding of MG1363 strain to fibronectin (Fig. 9B, black
bars), transferrin (Fig. 9B, white bars), or uncoated wells (data not shown) was observed,
demonstrating that L. lactis does not interact strongly with fibronectin or transferrin. In contrast,
MG1363 cells harboring plasmid pXL14 demonstrated significant (P = 0.001) binding to
immobilized fibronectin (Fig. 9B, black bars); these cells, however, did not bind to transferrin
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(Fig. 9B, white bars). Therefore, L. lactis cells expressing Shr gained the ability to specifically
bind to fibronectin. This observation demonstrates that Shr can mediate cell binding to the ECM
and supports its possible role as bacterial adhesin.
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Figure 9. Shr expressed on L. lactis cell surface promotes bacterial binding to fibronectin.
Cells of the wild type Lactococcal strain MG1363 and of a recombinant MG1363 strain
harboring plasmid pXL14 (MG1363/pXL14) were tested for Shr surface presentation and cell
binding to different ligands. (A) ELISA assay with immobilized L. lactis cells and anti-Shr
serum. Wells coated with L. lactis cells were reacted with anti-L. lactis serum (gray bar), antiShr serum (black bar), or with normal rabbit serum (white bar) as described in Materials and
Methods. (B) Analysis of L. lactis cell binding to immobilized fibronectin. L. lactis cells were
reacted with wells coated with fibronectin (black bar) or transferrin (white bar) as described in
Materials and Methods. Bound bacteria were detected with anti-L. lactis serum. Antibody
binding was detected with secondary AP-conjugated antibodies. Each bar represents the average
of at least four repeats, and the SD is represented by the error bars. The asterisks indicate
statistical significance for the differences between MG1363 and MG1363/pXL14 in Shrantiserum binding (A, P = 0.0037) and in binding to immobilized fibronectin (B, P = 0.001).
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To test the function of Shr in adherence of whole GAS cells directly, the shr mutant (ZE4912)
was compared to its wild type parent (NZ131) as well as to the mutant complemented with the
shr gene (ZE4924). Binding of GAS to HEp-2 cells was assayed following incubation at 37C
for 2 h. In comparison to the wild type strain, the shr mutant demonstrated about 40% reduction
in adherence (Fig. 10). This difference is statistically significant (P < 0.05). Although the
complemented strain bound to the HEp-2 cells better than the mutant, it only bound about 75%
as well as the wild type. The difference in binding between the complemented strain and either
the wild type or the shr mutant was not statistically significant. Thus, although complementation
was not complete, Shr seems to act as an adhesin in GAS attachment to HEp-2 cells.

Shr production and surface presentation is conserved among clinical isolates. A collection
of 17 clinical isolates representing seven different M serotypes was examined for Shr expression
using whole cell ELISA. As summarized in Table 1, Shr antiserum reacted with most of the
isolates (14 out of 17) and produced a signal that was at least 2 fold higher than the background
signal produced with the control serum NRS. A significant variation in the strength of the
produced signal was found among the different clinical isolates, however. This range of reaction
may result from differences in the amount of Shr protein produced by each strain or may be due
to antigenic differences in Shr and subsequently weaker interaction with the Shr antiserum. Shr
sequence is very conserved among GAS genomes available in the database, however the
sequence variability may increase among clinical isolates. In summary, Shr protein was present
on the surface in 17 out of the 20 strains tested in this study (including NZ131, MGS5005 and
JRS4), suggesting that this protein is important for the GAS infection process.
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Figure 10. Adherence of GAS to cultured epithelial cells.
Mid-log phase cultures of wild-type strain (NZ131), shr mutant (ZE4912), and the
complemented strain (ZE4924) were incubated with confluent HEp-2 cell monolayers for 2 h at
37 ºC under 5% CO2. Unattached bacteria were removed by washing, cells were detached and
lysed, and the number of bound bacteria per well was determined by plating. Each bar represents
the mean number of GAS cells attached as obtained from at least two independent experiments
performed in triplicate. The standard error of the mean (SEM) is expressed by the error bar. The
significance of the difference in adherence between the three strains was examined by ANOVA
(P = 0.025) followed by the Tukey’s HSD test for each strain pair. The asterisk indicates that the
difference between NZ131 and ZE4912 is statistically significant (P < 0.05).
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Table 1. Analysis of Shr expression on the surface of GAS clinical isolates.

(work was performed by M. Fisher (Fisher, Huang et al. 2008)).
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Shr is expressed by GAS in vivo and elicits an immune response in mice. In cells growing in
vitro in the laboratory, shr expression is regulated by the availability of metal in the medium
(Bates, Toukoki et al. 2005). To determine if the conditions in vivo during GAS infection in a
murine model allow the expression of Shr, we asked if a challenge with GAS leads to the
production of Shr antibodies in mice.

Mice were injected subcutaneously with strain

MGAS5005 (M type 1) and sera collected 28 days after inoculation were assayed by ELISA for
Shr antibody titer. Purified Shr was used to coat microtiter plates, which were then reacted with
the mouse sera (Fig. 11). Sera from mice injected with GAS reacted strongly with purified Shr
in most of the tested animals (9 out of 14), whereas none of the sera obtained from naïve mice
were reactive against Shr. The conversion of most mice to Shr positive demonstrates that Shr is
immunogenic, and that in most of the mice, it was produced during infection in sufficient
amounts and duration to elicit an immune response.
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Figure 11. Shr antibody levels in mice following recovery from GAS infections.
Mice were inoculated subcutaneously with a sublethal dose of MGAS5005 (M1). Serum was
collected from each mouse 28 days following challenge, diluted 1:1000, and tested for reactivity
with purified Shr by ELISA as described in the Methods. Each datum point represents the titer
obtained from an individual mouse. (work was performed by M. Fisher (Fisher, Huang et al.
2008)).
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Shr is important for GAS pathogenesis in the zebrafish infection model. The use of
zebrafish as an infection model for pathogenic streptococci was previously established.
Intramuscular injection (i.m.) of zebrafish with the native fish pathogen, S. iniae causes a
systemic disease, while injection with GAS causes mostly local muscle lesions and necrosis
(Neely, Pfeifer et al. 2002). The effect of shr inactivation on virulence was investigated via the
i.m. infection route, as previously described (Neely, Pfeifer et al. 2002; Montanez, Neely et al.
2005). Groups of six zebrafish were challenged with 106 CFU per fish of the wild type NZ131,
the shr mutant (ZE4912), or the mutant complemented with shr (ZE4924) cells (Fig. 12).
Injection with the wild type strain resulted in rapid fish death, with fish survival beginning to
decline as early as 12 h post infection, reaching a final survival rate of 22% at 48 h post infection
(filled squares). On the other hand, the shr mutant strain was attenuated for virulence; fish
injected with the mutant strain (open squares) exhibited a slower decline in survival and the final
survival rate was significantly higher than that of fish infected with the wild type strain (62%
survival at 48 h post infection, P < 0.0012).

The complemented strain (filled triangles)

demonstrated intermediate virulence; fish infected with this strain died at a slower rate than those
infected with the wild type strain (100% survival at 12 h and 24 h post infection). However, the
final survival rate eventually declined to a level similar to that of fish infected with the wild type
strain (25% 48 h post infection). Determination of LD50 was done by injecting each fish with a
range of 104-107 CFU of each strain. Consistent with the attenuated phenotype observed for the
shr mutant, the wild type LD50 value was significantly lower (5x104 CFU per fish) than that of
the mutant (2.5x106 CFU per fish), and an intermediate LD50 value (5.6x105 CFU) was observed
with the complemented strain, demonstrating partial complementation of virulence.
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The impact of Shr on the infection process in GAS was also evaluated by testing the ability of
the shr mutant to compete with the wild type strain for growth in the muscle tissue during coinfection.

Zebrafish were inoculated by i.m. injection with 106 CFU of a mixed culture

comprised of a 1:1 wild type to mutant ratio. The lesion area was excised 24 hours post
infection, and the number of viable bacteria of each strain in the tissue was determined by
comparing the bacterial recovery on plates with spectinomycin (the mutant’s marker) to that on
antibiotic-free plates. The competitive index (CI) is defined as the output ratio of mutant to
wild-type bacteria divided by the input ratio of mutant to wild type bacteria. The CI of the shr
mutant was calculated to be 0.011 ± 0.002. The growth rate of the shr mutant in vitro in THYB
was identical to that of the wild type strain. In addition, the chromosomal mutation in shr was
stable during growth in THYB in the absence of spectinomycin, as was evident from the plating
efficiency (100%) of this strain on selective plates after overnight growth in the absence of
antibiotics. Therefore, the low competition index suggests that inactivation of shr dramatically
reduced the in vivo fitness of GAS in comparison to the wild type strain in zebrafish tissue.
Since Shr is found both on the cell surface and in the culture supernatant, the fact that the
presence of the wild type strain during infection could not rescue the attenuated phenotype of the
mutant suggests that the surface associated form of Shr is important for GAS fitness during
infection.
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Figure 12. Zebrafish survival following intramuscular injection.
Kaplan-Meier plots showing survival of zebrafish following intramuscular challenge with 106
CFU of GAS wild type (NZ131, filled squares), shr mutant (ZE4912, open squares), and the
complemented (ZE4924, filled triangles) strains. The asterisk represent statistical significance
difference between ZE4912 (n = 18) and NZ131 (n = 56) (P = 0.0012) and between ZE4912 (n =
18) and ZE4924 (n = 12) (P = 0.03) by the log rank test.
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DISCUSSION
The human pathogen GAS exports numerous proteins to its surface where they carry out the
many tasks that mediate colonization and disease, Examples of these tasks include escape and
subversion of the immune response, adherence, and nutrient scavenging (Bisno, Brito et al.
2003). Shr is a large, complex, and highly conserved surface protein in GAS (Fig. 4A) that does
not share extensive sequence homology with other proteins in the database (Bates, Montanez et
al. 2003). Although the functional role of Shr has not yet been deciphered, this protein has been
shown to bind hemoproteins and is also suggested to mediate heme acquisition and transport in
conjunction with Shp and the SiaABC heme-transporter (Bates, Montanez et al. 2003; Nygaard,
Blouin et al. 2006). The major objectives of this study were to explore in depth the function of
Shr and its role in GAS pathogenesis. The results show that the contribution of Shr to the GAS
infection process extends beyond iron uptake to include interaction with ECM and adherence to
epithelial cells. Therefore, Shr represents a new MSCRAMM in GAS necessary for virulence in
the zebrafish model for necrotizing fasciitis.

When GAS is grown in culture under laboratory conditions, Shr is found in the supernatant as
well as in association with whole GAS cells. Even though Shr contains a leader peptide that can
mark proteins for secretion (Bates, Montanez et al. 2003), the mechanism that facilitates the
association of Shr with GAS surface remains unclear. The majority of surface proteins in Grampositive bacteria are covalently attached to the peptidoglycan by a sortase enzyme, which
recognizes a C-terminus cell wall sorting motifs followed by a hydrophobic segment and a
charged tail (Marraffini, Dedent et al. 2006; Scott and Barnett 2006). The LPXTG sequence
serves as the sorting signal for the housekeeping sortase in GAS. Shr does not have an LPXTG
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motif in its C-terminus or the QVPTG signal that is recognized by srtC2, an accessory sortase
that is also produced by the GAS NZ131 strain (Barnett, Patel et al. 2004).

Using cell

fractionation and immunobloting, this study demonstrated that Shr is not bound to the cell wall;
rather, Shr is found in the membrane fraction (Fig. 4B). The absence of recognizable cell well
sorting signals in Shr sequence is consistent with these findings. It seems likely that Shr remains
associated with the cytoplasmic membrane after its export to the surface due to the putative
trans-membrane segment and the charged tail found in its C-terminus (Fig. 4A), as was found to
be the case for ActA of Listeria monocytogenes (Kocks, Gouin et al. 1992). Shr is not present in
the membrane of the mutant GAS strain ZE4912, since the mutation is located in the 5’ coding
region of the shr gene and therefore results in the formation of a transacted protein secreted to
the culture supernatant (Fig. 5 and data not shown). The secretion of the abridged Shr fragment
supports the hypothesis that the C-terminus in Shr is required for its membrane anchoring and
therefore for its association with GAS cells.

The ability of anti-Shr serum to recognize Shr on the surface of whole GAS cells (Fig. 6, black
bars, NZ131 and ZE4924 strains) shows that the wild-type Shr protein spans the cell wall in
GAS and is exposed to the extracellular environment. Therefore, Shr may be able to interact
with large extracellular molecules, in addition to small ligands capable of diffusing the cell wall.
Since Shr appears to be anchored to the cytoplasmic membrane through its C-terminus, it is
possible that it can deliver heme from the extracellular compartment directly to the transport
components found in the cell membrane. This heme transport scheme is different from the one
proposed by Maresso et al. for heme uptake by the Isd proteins in S. aureus, where heme is
relayed in a cascade fashion from surface-exposed NEAT-proteins, such as IsdA, IsdB, or IsdH,
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to an IsdC protein that is found deeper in the peptidoglycan; heme is then transferred by IsdC to
the IsdDEF memebrane transporter for uptake (Maresso and Schneewind 2006).

Using solid phase binding assays, we were able to demonstrat that Shr also binds the ECM
components fibronectin and laminin (Fig. 7). The competition studies performed with soluble
and immobilized fibronectin and laminin demonstrate that Shr interactions with these adhesive
molecules are specific (Fig. 8). Therefore, Shr appears to have a broader spectrum of ligands
than previously suggested. Shr availability on the GAS surface combined with its affinity for
ECM components qualifies this receptor as a new MSCRAMM in GAS. The report also states
that recombinant L. lactis cells that express Shr on the surface binds specifically to immobilized
fibronectin (Fig. 9, MG1363/pXL14), which is an activity not found in the native L. lactis cells
(Fig. 9, MG1363). This observation shows that Shr is able to mediate bacterial attachment to the
ECM and further supports its role as a MSCRAMM. Interestingly, the Shr amino acid sequence
does not contain the typical fibronectin-binding repeats found in other fibronectin-MSCRAMMs
(Kreikemeyer, Klenk et al. 2004; Schwarz-Linek, Hook et al. 2006). Thus, it is not clear which
part of this large protein mediates the binding to fibronectin or to laminin. It was reported that
the NEAT-protein IsdA in S. aureus binds to several non-heme host proteins, including the ferric
carrier transferrin (Taylor and Heinrichs 2002), several matrix and plasma proteins, and
hemoglobin (Clarke, Wiltshire et al. 2004). The results presented here demonstrate that Shr does
not bind to transferrin, as it has a similar but not identical binding pattern as IsdA. The ligand
binding in IsdA is attributed to its single NEAT domain, but the residues involved in binding to
the serum and ECM proteins were not determined. The sequence homology between IsdA and
Shr is limited to the NEAT regions and is quite low even within these domains. Moreover, Shr is
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a significantly larger and more complex protein than IsdA (145 and 38 kDa respectively), and
has a central LRR segment, a unique amino terminal region, and two NEAT domains.
Additional analysis is required to determine the domains and the residues involved in the
recognition of various Shr ligands.

The data presented shows that Shr helps facilitate GAS attachment to HEp-2 epithelial cells,
where a reduction in binding of about 40% was observed in the shr mutant. This decrease in
adherence is statistically significant and can be partially restored in the complementation strain
(Fig. 10). Since GAS expresses several adhesins that mediate binding to HEp-2 cells, it is not
surprising that only a small reduction in adherence is observed in the shr mutant. As far as we
can determine, Shr is the only adhesin reported to be induced in response to the iron restriction
likely encountered during infection. Therefore, Shr’s contribution to adherence may be more
significant under such disease-specific conditions. Shr-dependent adherence may take place
through fibronectin binding or additional serum-bridging molecules as found for other GAS
adhesins (Kreikemeyer, Klenk et al. 2004; Talay 2005). Alternatively, Shr may interact directly
with a host cell receptor via a mechanism that may be assisted by its LRR domain (Fig. 4A).
LRR are suggested to provide a scaffold for the formation of protein-protein interactions (Kobe
and Kajava 2001), and the LRR domain in Internalin was shown to be necessary and sufficient
for binding to E-cadherin in L. monocytogenes (Lecuit, Ohayon et al. 1997).

It seems likely that shr complementation was not able to restore adherence to the level observed
in the wild type due to the nature of the mutation and the method used for complementation. The
shr mutation in ZE4912 results in the production of a truncated Shr fragment that is secreted into
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the extracellular medium. This Shr fragment, which is also produced by the complementation
strain, may serve as a competitor interfering with the Shr-mediated attachment to epithelial cells
and impairing adherence in the complementation strain. In addition, the complementation strain
ZE4924 is a merodiploid strain created by Campbell insertion. Since this type of mutation is
unstable, it may excise and reduce the efficiency of complementation in the binding assays.

This study presents several experiments that suggest Shr is important for GAS virulence. A
single infection event was found to be sufficient to trigger a significant antibody response to Shr
in convalescent mice, indicating that Shr is expressed in vivo in adequate amount and duration to
elicit a host response (Fig. 11). While the majority of the injected mice (9 out of 14) developed
high Shr titer, the anti-Shr antibody level in the remaining five mice was low. The observed
variations in the antibody response following GAS challenge may result from differences in the
time it took individual mice to clear the bacteria, or from variation in the efficiency of their
immune response, or both. Analysis of Shr production in different GAS strains, including a
collection of 17 clinical isolates (Table 1), revealed that Shr could be detected on the surface of
most of the examined strains. Inactivation of shr resulted in attenuation of virulence in a
zebrafish model (Fig. 12, ZE4912) with the LD50 of the mutant about 50 times higher than that of
the wild-type strain.

As in the adherence assay, only partial restoration of virulence was

observed with the complemented strain. Both the kinetics of survival in zebrafish post infection
and the LD50 value of ZE4924 complementation strain demonstrated an intermediate level of
virulence in comparison to the wild type NZ131 and the shr mutant ZE4912. This suggests that
either instability of the complemented strain or the production of both the full length and a
truncated fragment of Shr by ZE4924 prevented complete recovery of virulence. The recovery
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of the mutant strain from the lesion tissue was much less than that of the wild-type strain after
co-infection (CI of 0.01). This observation demonstrates that inactivation of shr results in a
mutant strain that is significantly less fit than the wild type parent strain. Shr is found both in the
culture supernatant and on the cell surface. The inability of the wild-type strain to complement
the in vivo growth defect of the mutant strain during co-infection of the zebrafish muscle
strongly suggests that it is the surface-anchored form of Shr that is important for GAS ability to
persist in the host during infection.

In summary, given that Shr is a broad-spectrum surface receptor contributing to iron acquisition
(Bates, Montanez et al. 2003) (and manuscript in preparation), ECM binding, and adherence, its
contribution to the disease process in GAS appears complex,. Ongoing research is on the way to
furthere investigate this important multi-functional surface protein and to better understand its
role in the disease process.
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CHAPTER II
DEFENSE FROM THE GROUP A STREPTOCOCCUS BY ACTIVE PASSIVE
VACCINATION WITH THE STREPTOCOCCAL HEMOPROTEIN RECEPTOR

INTRODUCTION

Streptococcus pyogenes or Group A Streptococcus (GAS) is a versatile pathogen capable of
producing a spectrum of illness ranging from mild infections such as pharyngitis and impetigo to
invasive diseases including myositis and necrotizing faciitis (Cunningham 2000).

GAS

infections can also trigger a number of disabling sequelae. For example, pharyngitis, an ordinary
childhood disease of which there are hundreds of millions of cases per year worldwide, can lead
to acute rheumatic fever (RF) in about 3% of the untreated patients (Steer, Danchin et al. 2007).
RF is thought to result from cross-reaction of antibodies and T cell receptors with tissues of the
heart, synovium, and/or neurons of the basal ganglia in the brain (Guilherme, Fae et al. 2005;
Guilherme, Ramasawmy et al. 2007). In addition to the induction of heart disease, the damage
inflicted by autoimmune reactions is hypothesized to produce a number of neuropsychiatric
disorders including Sydenhym’s chrea and obsessive-compulsive disorder (Snider and Swedo
2003; Snider and Swedo 2004). All together, GAS costs billions of dollars in the US alone and
more than 500,000 deaths per year globally. An effective GAS vaccine is therefore highly
desirable, especially for the developing parts of the world where RF and rheumatic heart disease
are leading causes of disability and mortality in children (Carapetis, Steer et al. 2005; Steer,
Danchin et al. 2007).
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GAS M protein has been extensively studied as a vaccine candidate since early observations that
it elicits lasting immunity (Cohen-Poradosu and Kasper 2007; Dale 2008; Steer, Batzloff et al.
2009). However, the antiphagocytic M protein is a highly variable antigen (Beall, Facklam et al.
1996; Facklam, Martin et al. 2002). The N-terminal domain, the molecule’s most outward facing
and least conserved region, evokes a M type specific antibody (Lancefield 1962). More than 150
of M types are known, and the number and identity of the prevalent strains varies significantly in
different parts of the globe (Kaplan, Wotton et al. 2001; Shulman, Tanz et al. 2009; Steer, Jenney
et al. 2009). In addition to the complications arising from extensive antigenic variation, M-based
vaccination programs suffer from safety concerns. Several M serotypes were implicated in RF
development, and cross reactivity has been found between some M epitopes and human tissues.

Recent studies suggest that a safe and effective M–base vaccine for GAS may be in reach. Two
vaccines based on peptides derived from the N-terminal domain of the M protein were found to
be protective in clinical trials without adverse outcome (Kotloff, Corretti et al. 2004; McNeil,
Halperin et al. 2005). In its current formulation, M vaccine provides protection against 26
serotypes, covering approximately 85% of GAS strains in the US (Shulman, Tanz et al. 2009).
Nevertheless, this vaccine is expected to have fairly limited coverage in the developing
countries, and there are concerns that it may trigger a shift in serotype prevalence (Steer, Magor
et al. 2009). Therefore, there is a significant interest in identifying additional protective antigens
that may facilitate broad immunization programs. A number of GAS components have been
investigated, including antigens derived from virulence factors or surface components, such as
the C5a peptidase (Ji, Carlson et al. 1997), the conserved C-terminal region of the M protein
(Pandey, Batzloff et al. 2009), group A carbohydrates (Sabharwal, Michon et al. 2006),
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lipoteichoic acid (Dale, Baird et al. 1994; Yokoyama and Harabuchi 2002) and several
fibronectin binding proteins (Kawabata, Kunitomo et al. 2001; Courtney, Hasty et al. 2003;
McArthur, Medina et al. 2004). Antigens that were identified in silico and/or by proteomics or
genomics methods have been also studied (Rodriguez-Ortega, Norais et al. 2006; Turner,
Kurupati et al. 2009). Although a protective response was observed with some antigens in one or
more models, difficulties arising from limited expression among GAS isolates or the high
concentration required for effective antibody response were reported. Other than the N-terminus
peptides of the M protein, no additional GAS antigens have reached human trails since the
1970s.

The streptococcal hemoprotein receptor (Shr) is highly conserved in GAS genomes. It binds to
several hemoproteins and ECM components and is implicated in iron acquisition and adherence
(Bates, Montanez et al. 2003; Fisher, Huang et al. 2008). Shr is available on the bacterial surface
for antibody binding, and recent analysis confirmed the expression of Shr in 14 out of 17 tested
clinical isolates representing 12 M types (Fisher, Huang et al. 2008). Here, we investigate the
ability of Shr to elicit protective immunity. We show that Shr is highly immunogenic and that
vaccination with Shr in both active and passive models protected mice from systemic GAS
challenge.
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MATERIALS AND METHODS

Bacterial strains and growth conditions.

E. coli DH5 harboring plasmid pCB1, which

expresses a recombinant Shr protein (His6-Xpress-Shr, rShr (Bates, Montanez et al. 2003)), were
grown in Luria-Bertani broth at 37ºC. The GAS strains MGAS5005 (M type 1 (Sumby, Porcella
et al. 2005)), MGAS315 (M type 3 (Beres, Sylva et al. 2002)) and ZE491 (M type 49, mtsR(Bates, Toukoki et al. 2005)) were grown at 37ºC in Todd-Hewitt broth (Difco Laboratories)
with 0.2% w/v yeast extract (THY). The Lacococcus lactis MG1363 and MG1363 harboring
plasmid pXL14 (expressing the native Shr protein (Fisher, Huang et al. 2008)) were cultivated in
M17 (Difco Laboratories) supplemented with 0.5% w/v glucose (GM17) at 30ºC.

When

necessary, ampicillin (100 g/ml) or kanamycin (70 g/ml) was added to the medium.

Mouse vaccinations. CD-1 female mice were used (weight, 20 to 22 grams; Charles River
Laboratories). For systemic immunization, recombinant Shr was purified as previously described
(Fisher, Huang et al. 2008) and was quantified using the Modified Lowry Protein Assay Kit
(Thermo Scientific). Purified rShr protein (40 μg) was administered intraperitoneally (i.p.) on
days 0 (emulsified in Complete Freund’s adjuvant, CFA), 14, 28, and 42 (emulsified in
Incomplete Freund’s adjuvant, IFA). For mock vaccination, phosphate-buffered saline (PBS)
mixed with CFA or IFA was administrated. Serum samples were collected on days 0, 7, 21, 35
and 49, and the anti-Shr immunoglobulin (Ig) G response in individual animals was determined.
Mucosal immunization was done as previously described (Quigley, Hatkoff et al. 2010). L. lactis
cells (MG1363/pXL14 or MG1363) were briefly washed and resuspended in saline to give 1 x
108 CFU/μl. Mice were vaccinated intranasaly (i.n.) by four administrations of 2 x 109 CFU (20
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μl) into the nostril, every 10 days for three consecutive days (i.e. on days 1, 2, 3, 14, 15, 16, 27,
28, 29, and on days 40, 41 and 42). The anti-Shr IgG titer in serum samples collected on day 50
was determined.

Lung lavage samples were collected on day 52 as previously described

(Quigley, Hatkoff et al. 2010), and the anti-Shr IgA level was determined.

For passive

immunization, 100 μl of rabbit rShr-antiserum (Bates, Montanez et al. 2003) or serum samples
from naive animals (normal rabbit serum, NRS) were mixed with 400 μl PBS and administrated
intraperitoneally. All of the vaccination and mouse challenge experiments were repeated at least
twice.

GAS infection model. GAS cells at the mid-logarithmic phase (OD600 = 0.7) were harvested,
washed and resuspended in saline. Cell concentration was determined by microscopic counts
and verified by plating. Mice were infected with 0.1 ml of cells suspension (LD80) and were
observed four times a day after challenge. Animals exhibiting signs of severe distress were
euthanized and counted as dead. All experiments involving animals were conducted according
to protocols approved by the Georgia State University Institutional Animal Care and Use
Committee.

Shr-antibody detection.

The antibody response was measured by enzyme-linked

immunosorbent assay (ELISA) (Quigley, Hatkoff et al. 2010). Briefly, microtiter plates (Costar,
Corning Inc.) were coated with rShr (50 ng per well), washed and blocked with 1% w/v BSA in
PBS-Tween. Serum or lung fluid samples were allowed to react with the coated plates for 1 h at
37ºC. Antibody production was detected using anti-mouse IgG or anti-mouse IgA secondary
antibodies (Sigma).

The absorbance at 405 nm was measured after a 30-min incubation.
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Antibody titers were defined as the dilution producing the same OD405 at 2 times of the
background level (the reading obtained with serum or lung fluid samples of nonimmunized
mice).

Opsonophagocytic killing assay. ZE491 GAS cells (OD600 = ~0.7) were harvested and washed.
A total of 0.1 ml of diluted (1: 200,000) cell samples were added into 0.5 ml of fresh rabbit
whole blood, together with 0.1 ml of rabbit Shr antiserum (Bates, Montanez et al. 2003) or NRS
(as control), and incubated with shaking at 37ºC for 3 h. Surviving bacteria were enumerated by
plating for viable counts. Opsonization expressed as the percent reduction in mean CFU was
calculated as [1 – (CFU in the presence of Shr antiserum)/ (CFU in the presence of NRS)] x 100
(Olive, Sun et al. 2006).

Statistical analysis. Data presented are average or representative of data from experiments
repeated at least two times.
comparing two groups.

The Student’s t test was used for testing significance when

Kaplan-Meier plots of survival and log-rank tests were used for

comparison of protection by immunization.
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RESULTS

Intraperitoneal vaccination with Shr elicits a robust humoral response and protection.
Previous studies demonstrated that Shr is expressed in vivo and suggested that it is required for
GAS disease process (Fisher, Huang et al. 2008), raising the possibility that the multifunctional
Shr may serve as a vaccine target. To examine Shr antigenic potential, a recombinant protein
(rShr, (Bates, Montanez et al. 2003)) was expressed, purified and administrated intraperitoneally
to mice. The time course development of the anti-Shr response was monitored in serum samples
from four representative mice (Fig. 13A). All four animals developed a significant serum
reaction to Shr after a single antigen administration (IgG titer range, 103-104). The anti-Shr IgG
level continued to ascend after the second immunization and appeared to be saturated after the
third immunization, demonstrating an anti-Shr titer range of (1.25 - 6.25) x 106. End point titer
analysis in the rest of the cohorts’ mice revealed a robust anti-Shr response in the immunized
animals, with a mean titer of 5.6 x 105 (Fig. 13B). In contrast to the significant anti-Shr response
found in the experimental group (ie, Shr-immunized mice), Shr-specific antibody was not seen in
serum samples obtained from the control group (ie, the mock vaccination group).

To test for protective immunity, vaccinated mice were challenged i.p. with a lethal dose of
MGAS5005 (M type 1) on day 49 of the vaccination experiment, and animal survival was
monitored for 5 days. A rapidly progressing fatal infection developed in most of the mice in the
control group (mock vaccination), resulting in 21% survival at the end point. Similarly, an
aggressive disease was previously reported in a murine model for systemic GAS infection with
MGAS5005 (Sumby, Porcella et al. 2005). A less severe disease developed after infection of
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mice immunized with rShr, and the end point survival rate of this group was 78%, 3.7-fold
higher than that of the mock-vaccinated group (P = 0.002) (Fig. 14). Therefore, systemic
immunization of mice with rShr provides protection from systemic GAS challenge.
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Figure 13. Anti-Shr response in serum after intraperitoneal vaccination.
Mice were administrated with rShr (arrow heads), and the resulting serum IgG titers were
determined by ELISA performed in quadruplicates. Each datum point represents the average
response in individual animals. (A) Shr antibody development. Shr-specific IgG levels were
determined in serum samples collected from 4 representative mice on days 0, 7, 21, 35 and 49.
(B) End point anti-Shr IgG response. The anti-Shr IgG titers found in serum samples collected on
day 49 from mice administrated with rShr (Shr-immuned; n=19) or with PBS (mock; n=10) are
shown. The horizontal bar indicts the mean titer response.
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Figure 14. Protection of mice from systemic GAS challenge after intraperitoneal
vaccination with Shr.
Immunized mice were infected intraperitoneally with 5 x 108 CFU. Kaplan-Meier survival
curves of antigen-immunized mice (shr; n=18) and mock-vaccinated mice (PBS; n=14) are
shown. The statistical significance (P = 0.002) was determined by the log-rank test. Two
independent experiments producing similar results were conducted; the data shown are from a
representative experiment.
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Intranasal vaccination with Shr results in strong antibody response and enhanced defense.
The ability of Shr to elicit immune response by mucosal vaccination was examined using the
probiotic L. lactis as a delivery vector. Mice intranasally received the recombinant bacteria
expressing Shr on the surface (MG1363/pXL14, (Fisher, Huang et al.)) or the native host cells
(MG1363). The presence of anti-Shr IgA in undiluted lung lavage samples collected 10 days
after the last antigen administration (day 52) was determined by ELISA. A measurable Shr-IgA
activity was exhibited by all of the mice that were immunized with Shr-expressing bacteria (Fig.
15A); 9 out of 13 mice developed a Shr-specific IgA level that was at least three times higher
than that seen in untreated animals (with an end point IgA titer (the titer is expressed as a dilution
ratio) that varied from 1:4 to 1:64; data not shown). Mice that were vaccinated with unmodified
L. lactis cells showed only the background IgA level seen with untreated animals (P = 0.01).
The induction of anti-Shr IgG in the serum after the course of mucosal vaccination (day 50) was
tested as well (Fig. 15B).

All of the mice administrated with the recombinant L. lactis

(MG1363/pXL14) developed a significant IgG response to Shr, demonstrating a mean endpoint
titer (+ standard deviation) of 5.5 x 104  2 x 104, whiereas only background response was found
in serum samples from pre-immune mice or mice vaccinated with native L. lactis (MG1363, P <
0.0001).

Therefore, mucosal administration with L. lactis expressing Shr resulted in a

measurable immune response in secretions and a strong reaction in the serum.

We next asked whether the anti-Shr immune response triggered by the mucosal immunization
was sufficient to protect against GAS infection. Vaccinated mice were infected intraperitoneally
(on day 52) with MGAS5005. Aggressive infections were seen after the challenge in mice that
were immunized with the native L. lactis strain (MG1363), demonstrating only a 25% survival
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rate on the fifth day after infection. In contrast, most of the mice that were administrated with
Shr-producing lactococci (MG1363/pXL14) were able to recover and demonstrated an 87%
survival rate, 3.48-fold higher than that of the control group (P = 0.014) (Fig. 15C). Thus,
mucosal immunization with Shr-producing bacteria resulted in protective immunity against
systemic GAS challenge.
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Figure 15. Shr intranasal vaccination and protective immune response.
Mice were immunized with 2 x 109 CFU of L. lactis (MG1363) or L. lactis expressing Shr
(MG1363/pXL14). Endpoint antibody response (on day 50 and 52, respectively) was determine
by ELISA preformed in quadruplicate. (A) Shr-specific IgA level in undiluted lung lavage
specimens from mice treated with MG1363 (n=2) or MG1363/pXL14 (n=13). Each datum point
represents the mean response in individual animals. The statistical significance (P = 0.01) was
determined by the Student t test. (B) Shr-specific IgG titer in serum from individual mice treated
with MG1363 (n=15) or with MG1363/pXL14 (n=15). The statistical significance (P < 0.0001)
was determined by the Student t test. (C) Kaplan-Meier survival curves of vaccinated mice after
systemic GAS challenge. Mice immunized with MG1363 (n=8) or MG1363/pXL14 (n=8) were
intraperitoneally received 1 x 108 CFU. The statistical significance (P =0.014) was determined
by the log-rank test. The data shown are pooled data from two independent experiments.

69
Passive immunity with rabbit Shr antiserum. The studies described above show that Shr
vaccination administered via both the intraperitoneal and intranasal routes resulted in significant
serum anti-Shr IgG. To examine whether the observed humoral response to Shr could account
for the protection exhibited by the vaccinated animals, we tested the ability of rabbit Shr
antiserum (Bates, Montanez et al. 2003) to protect naive mice from upcoming GAS infection.
Pretreatment of mice with Shr antiserum (with a titer of 106) prior to intraperitoneal inoculation
of MGAS5005 provided significant defense; the survival rate at the end point for mice
administrated with the Shr antiserum was 60%, whereas only a 20% survival rate was observed
with the control mice that were treated with NRS prior to the challenge (P = 0.0308) (Fig. 16A).
The same Shr antiserum also defended mice from infection with the invasive M type 3 strain
MGAS315, demonstrating 53% and 20% survival rates in mice treated with anti-Shr or NRS,
respectively (P = 0.034) (Fig. 16B). These observations indicate that Shr antibodies are
protective against multiple GAS serotypes and suggest that the defense from GAS obtained by
vaccination is mediated at least in part by serum antibody to Shr.

Rabbit Shr-antiserum is bactericidal. Because rabbit Shr-antiserum protects mice from GAS
infection, we tested whether it contains opsonizing antibodies.

The GAS metal-dependent

repressor, MtsR, represses the expression of Shr in vitro (Bates, Toukoki et al. 2005). To ensure
Shr production under the experimental conditions, we used the mtsR mutant, ZE491, in which
Shr expression is deregulated (Bates, Toukoki et al. 2005). ZE491 cells were allowed to grow in
rabbit whole blood in the presence of Shr-antiserum or NRS, and the change in the bacterial load
after 3 hours of incubation was determined by viable counts. A significant reduction in the
bacterial number (mean + standard deviation, 70%  17 %) was observed in cultures treated with
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Shr antiserum, comparison with those that were treated with NRS (Fig. 17), indicating that the
anti-Shr serum facilitates phagocytosis and bacterial killing in whole blood.
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Figure 16. Protection of mice from systemic GAS infection with passive immunization with
anti-Shr.
Kaplan-Meier survival curves are shown for mice challenged with 5 x 107 CFU 4 h after
intraperitoneal administration of rabbit Shr antiserum (anti-Shr) or with normal rabbit serum
(NRS). (A) MGAS5005 challenge. The results are representative of two independent
experiments (n=10 for both groups; P=0.0308). (B) MGAS315 challenge. The data shown are
pooled from three independent experiments (n=15 for both groups; P=0.034). The statistical
significance was determined by the log-rank test.
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Figure 17. Serum mediation of phagocytosis and killing of bacteria with anti-Shr.
ZE491 cells were incubated in rabbit whole blood in the presence of Shr antiserum or normal
rabbit serum (NRS). Bacterial growth after 3 h of incubation with Shr antiserum was compared
with that of control NRS. The mean opsonization percentage (measured as the percentage
reduction in CFU) derived from 4 independent experiments is shown; the standard deviation
(SD) is represented by the error bar (P < 0.001).
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DISCUSSION

An effective prevention program for GAS is greatly needed, especially in the developing world,
where antibiotic therapy fails to control the occurrences of rheumatic fever and rheumatic heart
disease as it does in developed countries (Guilherme, Ramasawmy et al. 2007; Steer, Danchin et
al. 2007; Steer, Jenney et al. 2009). The increasing reports of drug-resistant GAS further
underscore the need for GAS vaccine (Ardanuy, Domenech et al. 2010; Feng, Lin et al. 2010;
Ikebe, Wada et al. 2010; Malli, Tatsidou et al. 2010). The hyper-variable M protein is the most
prominent and promising GAS antigen (Kotloff, Corretti et al. 2004; McNeil, Halperin et al.
2005). However, M-based vaccination would likely require unique formulation for different
geographic areas, and the efficacy of the vaccine may be hampered by rapid changes in GAS
populations. Conserved antigens, which can be used alone or in combination with M-epitopes to
increase coverage and combat population shifts, are therefore required. Here, we show that a
conserved protein, Shr, is a promising antigen that can elicit robust humoral response and
provide defense from systemic GAS infections in both active and passive immunization models.

We previously reported that GAS infection led to serum conversion in most of the surviving
mice (Fisher, Huang et al. 2008). In this study, we measured the serum immune response
triggered by Shr vaccination using CFA/IFA or L. lactis as adjuvants in systemic and mucosal
application, respectively.

The vigorous Shr-specific IgG response developed in mice after

intraperitoneal vaccination (Fig. 13), and the high antibody levels observed in the intranasally
immunized animals (Fig. 15B), together suggest that Shr is a strong immunogen. Moreover,
both vaccination protocols resulted in enhanced resistance to systemic GAS challenge, showing
that the immune reaction to Shr is protective (Fig. 14 and 15C). It is interesting to note,
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however, that although the mucosal antigen administration produced a lower anti-Shr IgG titer
((5.5 x 104  2 x 104) than did intraperitoneal vaccination with rShr (5.6 x 105), a similar level of
mouse recovery from GAS infection was seen in both cases.

Immunization with L. lactis

typically leads to a T-helper 1 (Th1)-biased response (Repa, Grangette et al. 2003; Hanniffy,
Carter et al. 2007; Quigley, Hatkoff et al. 2010). In addition to supporting IgG2a production
over other immunoglobulin subtypes, Th1 adaptive response promotes cellular immunity, which
could complement the protection provided by serum IgG.

Mucosal immunity is an important prevention and control measure of mucosal pathogens such as
GAS. Lactococcus species was previously used successfully to elicit mucosal defense against
Streptococcus pneumonia, Group B Streptococcus, and Group A Streptococcus (Buccato,
Maione et al. 2006; Hanniffy, Carter et al. 2007). Here, we show that in addition to the strong
production of serum antibody, intranasal immunization with L. lactis expressing Shr triggered
anti-Shr IgA formation in secretions (Fig. 15A). Shr-specific IgA was seen in the lung lavage
specimens obtained from most mice, although the antibody titer was modest.

Mucosal

vaccination with M-derived peptides provided protection from intranasal challenge even in the
absence of strong IgA response, suggesting a protective role for serum IgG (Olive, Clair et al.
2002; Olive, Sun et al. 2006). Nevertheless, IgA is important for GAS defense (D'Alessandri,
Plotkin et al. 1978; Kawabata, Kunitomo et al. 2001; Batzloff, Pandey et al. 2006); thus, the
mucosal delivery of Shr needs improvement. Investigations of alternative mucosal adjuvants,
such as the lipid core peptide (Olive, Sun et al. 2006), proteosomes (Jones, Allard et al. 2003), or
GAS pilus-based UPTOP (for unhindered presentation of polypeptides on tips of pili) system
(Quigley, Hatkoff et al. 2010), are warranted.
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Mice that were administrated with anti-Shr rabbit serum prior to infection demonstrated
significantly higher survival rates after challenge with MGAS5005 or MGAS315 (60% and 53%,
respectively) than did mice treated with NRS (20%) (Fig. 16). The observation that humoral
response to Shr is protective suggests that the defense conferred by active vaccination with Shr is
mediated, at least in part, by serum antibodies.

Protection by serum antibodies is further

supported by the findings that Shr antiserum is bacteriocidal (Fig. 17). In addition to facilitating
GAS clearance by phagocytes, Shr serum antibodies are likely to interfere with Shr iron
acquisition and adherence (Bates, Montanez et al. 2003; Fisher, Huang et al. 2008) and thus may
act directly to limit GAS growth and spread. The observation that Shr confers passive immunity
suggests that Shr antiserum may be useful in therapy of invasive diseases, such as streptococcal
toxic shock syndrome (STSS). STSS is a rapidly progressing, superantigen-mediated disease
that involves bacterimia, hypotension and multi-organ failure (Johansson, Thulin et al. 2010).
The absence of protective antibodies against GAS M protein and superantigens is found to be
associated with higher risk for STSS.

Effective GAS antibodies may be useful in STSS

treatment as they may act in reducing the bacterial load in the blood and thus superantigen
production.
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CHAPTER III
ANALYSIS OF SHR DOMAINS

INTRODUCTION
Shr is a conserved heme-acquiring protein that binds in vitro to hemoglobin, myoglobin and
hemoglobin-haptoglobin complex (Bates, Montanez et al. 2003). We recently identified Shr as a
new MASCRAMM that mediates GAS attachment to epithelial cells and contributes to the
infection process (Fisher, Huang et al. 2008). Shr is exposed to the extracellular environment
while the C-terminus of the receptor is tethered to the cell membrane. Purified Shr specifically
interacts with the host ECM proteins fibronectin and laminin and its expression by Lactococcus
lactis allows the recombinant bacteria to bind to immobilized fibronectin. These observations
suggest that fibronectin binding is important for the role of Shr in adherence. In vivo, Shr
contributes to virulence in an intramuscular zebrafish infection model and a high titer of Shr
antibody was observed in sera from convalescent mice. Immunization studies in murine models
revealed that intraperitoneal administration of Shr triggers a robust production of Shr-specific
IgGs in the serum (Huang, Fisher et al. 2011). Intranasal immunization with recombinant L.
lactis that expresses Shr elicits a specific IgA reaction in the lung lavage and a strong IgG
reaction in the serum. Both immunization routes provide protection from systemic GAS
challenge. In addition, rabbit Shr antiserum is bactericidal in vitro and defends from GAS disease
when administrated to mice prior to challenge. Overall, these findings suggest that Shr is a
promising vaccine candidate. We inferred that the contribution of the multifunctional Shr to GAS
pathogenesis and its promise as a protective antigen merit more detailed studies of its structural
domains.
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Shr contains two NEAT (NEAr Transporter) domains. Andrade et al (2002) identified the NEAT
domain (~125 amino acids) in genes from Gram-positive pathogens that are located near
transporters of iron complexes. Up to five copies of the NEAT domain were found in a single
protein. Although low sequence homology can be shared by separate NEAT domains, they are
suggested to have similar secondary structure that consists mainly of -strands. Our search for
the NEAT structure in the PDB (Protein Data Bank, http://www.rcsb.org/pdb/) (Bernstein,
Koetzle et al. 1977) showed that the NEAT domains are folded into an immunoglobulin-like sandwich structure.

Shr NEAT domains are separated by a leucine rich repeat (LRR) region. In addition, this
complex protein contains a leader peptide and two copies of the DUF1533 motif (Fig. 4). The
different regions in Shr are likely to facilitate its interactions with multiple host ligands. Shr
protein modules and sequence motifs are found in different combinations in a variety of proteins
from important Gram-positive pathogens. The NEAT domains, for example, are typically located
in exported or secreted proteins. All of the NEAT-proteins characterized to date are parts of
proteins that are involved in heme uptake. The Isd (iron-regulated surface determinants) system
in Staphylococcus aureus includes the best characterized NEAT proteins. A few proteins in
Bacillus species and Clostridium novyi contain a LRR region in addition to one or more NEAT
modules. DUF1533 motif is found in variable copies with or without additional domains mostly
in proteins that are predicted to be on the bacterial surface. Shr presents the only proteins type in
the database, in which the NEAT, LRR and DUF1533 domains appear together. In addition to
GAS, Shr orthologues are found in a few human and animal pathogens. These include the toxinproducing C. novyi and the pyogenic Streptococcus dysgalactiae, Streptococcus equi subsp.
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zooepidemicus and equi. The shr gene in S. equi subsp. equi has a nonsense mutation that leads
to the production of a truncated version of Shr, containing the N-terminal part of the proteins
with two copies of DUF1533 and a partial NEAT domain (Meehan, Burke et al. 2010). Shr
orthologues in Streptococcus share high amino acid homology (58-86% identity) (Fig. 18). The
orthlogue in C. novyi is more remote and exhibits limited sequence similarity (30%) (Meehan,
Burke et al. 2010; Ouattara, Bentley Cunha et al. 2010). The presence of domains that are shared
by several proteins from important pathogens raises the possibility that a broad-spectrum vaccine
could be developed based on Shr protein modules.
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Figure 18. Shr proteins in pyogenic streptococci and Clostridium novyi.
LP: leader peptide; DUF: domain of unknown function 1533; NEAT: NEAr Transporter domain;
EF: EF-hand motif; TM: transmembrane domain. (Figure adopted from Ouattara, Bentley Cunha
et al. 2010)
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Gram-positive bacteria express a wide variety of MSCRAMMs with fibronectin binding ability.
These adhesins share overall structural organization and binding mechanism, while the protein
lengths in each case vary greatly (Schwarz-Linek, Hook et al. 2006). The major fibronectinbinding activity in these molecules is typically localized to a region with tandem repeats of 35-40
amino acids, named FnBR (fibronectin binding repeat). FnBRs are typically found in the Cterminal half of the adhesin. The number of FnBRs varies among individual adhesins, but the
repeating unit shares significant sequence homology (Fig. 19A). FnBR targets the N-terminal
domain of fibronectin, which consists of five copies of the Fn-type 1 module (1-5F1) (Fig. 2). The
binding mechanism was deciphered by NMR study of a paired FnBR/Fn (1F12F1 in Fig. 19).
This investigation revealed an anti-parallel orientation of the binding partners with an additional
-strand, and the binding mechanism was termed the tandem -zipper model (Fig. 19B)
(Schwarz-Linek, Werner et al. 2003). The structural information provided by the FnBR of S.
dysgalactiae allowed the identification of the pattern and numbers of the FnBR repeats in the
larger fibronectin-binding protein SfbI (GAS) and FnBPA (S. aureus). In SfbI, FnBPA and other
fibronectin-binding proteins, an additional upstream fibronectin-binding domain (UFBD) is
found (Fig. 19A). In FnBPA, the B1-B2 regions and repeats 4-5 are considered as the upstream
fibronectin-binding domain. This region is known to use the same binding mechanism to the Fntype 1 module as the FnBRs. The upstream fibronectin-binding domain (UR) of SfbI binds to an
additional binding site, the gelatin-binding fragment in fibronectin. Therefore, the UR serves to
enhance SfbI binding the ECM protein (Fig. 19A).
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Figure 19. The extended tandem -zipper model.
A, Schematic presentation of SfbI and FnBPA showing 1-5F1-binding repeats (green and orange
boxes). S, signal peptide. W, cell wall recognition motif. M, cell membrane spanning region. In
SfbI, UR represents the upstream FN-binding domain. In Fn BPA, B1-B2 and box 4-5 represent
the upstream FN-binding domain. B, The extended tandem -zipper model. A 1-5F1-binding
segment is shown (grey line) with the binding -strand (navy blue) of five sequential modules of
consensus F1 fold (light blue). (Figure adopted from Schwarz-Linek, Werner et al. 2003)
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The absence of the typical FnBPs and UFBD described above in Shr is intriguing and suggests
that Shr binds to fibronectin using a different binding module(s) (Fig. 4A). NEAT domains have
diverse ligand specificity, some interact only with heme while others bind heme and/or hemecontaining proteins, such as hemoglobin and hemoglobin-haptoglobin complex (Grigg,
Vermeiren et al. 2007). The single NEAT domain of IsdA, has an unusually wide spectrum of
ligands. These include several serum proteins (fetuin, asialofetuin, transferrin and hemoglobin)
and the ECM components, fibrinogen and fibronectin (Clarke, Wiltshire et al. 2004). This
observation suggests the implication of Shr NEAT domain in ECM binding.

NEAT domains are distributed in a collection of proteins involved in iron scavenging in
important Gram-positive pathogens. Many of them are negatively regulated by iron. The NEATreceptors are typically expressed during infection since iron is highly limited in the human body.
NEAT proteins have been drawing an increasing attention in the development of new strategies
to prevent and treat staphylococcal diseases. Recently, an investigation of cell wall proteins in S.
aureus identified two NEAT proteins, IsdA and IsdB, as potential vaccine candidates (StrangerJones, Bae et al. 2006). In addition, Kuklin et al reported that immunization with IsdB induced
rapid antibody responses in rhesus macaques and increased the survival of infected animals in a
murine sepsis model. The protection observed in this study correlates with the IgG titer found in
the infected animals (Kuklin, Clark et al. 2006). The immunity elicited by IsdA and IsdB is
suggested to be mediated by antibody interference with heme acquisition (Kim, DeDent et al.
2010). However, none of these studies has identified the protective epitopes in IsdA and IsdB.
The structural homology of different NEAT domains may provide common protective epitopes
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in NEAT proteins, including Shr. In this chapter, we analyze the functions and antigenic
properties of Shr domains using isolated Shr fragments and antisera raised against them.

84
MATERIALS AND METHODS
Bacterial strains and growth conditions. E. coli DH5 and TOP10 were used for cloning and
maintenance of plasmids. E. coli XL1 Blue, XL10 Gold and BL21 Star™ (DE3) were used for
recombinant protein expression. The GAS strains used in this chapter were NZ131 (wild type),
ZE4912 (a shr deletion-insertion mutant made by replacing an internal fragment with the
spectinomycin resistance gene aad9) (Fisher, Huang et al. 2008) and the following GAS mutants
with in-frame deletion of various shr regions: ZE4925 (ΔNEAT1), ZE4926 (ΔNEAT2), ZE4929
(ΔNEAT1-2) (Ouattara, Bentley Cunha et al. 2010). In addition, we used the GAS strains ZE491
(an mtsR mutant) (Bates, Toukoki et al. 2005), MGAS5005 (M type 1) and MGAS315 (M type
3). The Streptococcus dysgalactiae subsp. equisimilis strain ATCC 12388 (Vandamme, Pot et
al. 1996) was used to clone shr. E. coli cells were grown in Luria-Bertani broth at 37ºC.
Streptococcus cells were grown at 37ºC in Todd-Hewitt broth (Difco Laboratories) with 0.2%
w/v yeast extract (THY). When necessary, ampicillin at 100 g/ml or kanamycin at 70 g/ml
was added to the growth medium.

DNA methods. Chromosomal DNA extraction was performed by MasterPure™ Gram Positive
DNA Purification kit (Epicentre). Plasmid DNA was purified with Wizard® plus Minipreps
(Promega). PCR for cloning was performed by using AccuTaq DNA Polymerase (SigmaAldrich). PCR products were purified with QIAquick PCR Purification kit (Qiagen). DNA
manipulations including restriction digests, ligation and DNA transformation were done
according to the manufacturer’s recommendation and with standard protocols (Sambrook 1989).
The oligonucleotide primers used are listed in Table 2. The plasmids used are listed and
described in Table 3.
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Construction of protein expression vectors. (i) Construction of the vectors expressing His6maltose-binding protein (MBP)-tagged NEAT1 (pYSH6) or NEAT2 (pYSH8). To generate
the expression vectors for the His6-MBP fusion proteins, we used the two-step cloning approach,
Gateway® Technology with Clonase II system by Invitrogen (Hartley, Temple et al. 2000). The
Gateway® Technology is based on the bacteriophage lambda site-specific recombination system,
which facilitates the integration of lambda DNA into the E. coli chromosome. Naturally, lambdasite-specific recombination occurs between the attB site on the E. coli chromosome and the attP
site on the phage genome. This reaction results in two recombinant attL and attR sites to the
lambda genome (Landy 1989). The first cloning step involves a recombination reaction (BP)
between an attB-flanked DNA fragment of choice and an attP-containing donor vector. This
reaction produces the entry clone (Fig. 20A). The resulting clone is then used in a second
recombination (LR) with a destination vector (pDEST-HisMBP), which contains a His6-MBP tag
(Nallamsetty, Austin et al. 2005). This reaction, which is taking place between the attL on the
entry clone and the attR of the destination vector, generates the expression vector with His6MBP fusion protein. The entry clones in this study were generated using DNA fragment
containing the NEAT coding sequences amplified from the NZ131 chromosome using primers
with attached attB sites. The resulting fragments were then cloned into the pDONR™ 221 by BP
Clonase™ II. The recombinant entry clones were selected on kanamycin (50 µg/ml). The
NEAT1 (pYSH5) and NEAT2 (pYSH7) entry clones (Fig. 21 and Fig. 22, respectively) were
reacted with the destination vector pDEST-HisMBP, using LR Clonase™ II. These reactions
generated the expression vector pYSH6 (His6-MBP-NEAT1) and pYSH8 (His6-MBP-NEAT2),
which were selected on ampicillin (100 µg/ml) (Fig. 23 and Fig. 24). The identity and orientation
of each insert were verified by restriction enzyme and DNA sequence analysis. (ii) Construction
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(A)

(B)

Figure 20. Gateway® Recombination reactions.
Two recombination reactions constitute the basis of the Gateway® Technology. (A) BP reaction
facilitates recombination of an attB substrate (attB-PCR product) with an attP substrate (donor
vector) to create an attL-containing entry clone. This reaction is catalyzed by BP Clonase™ II
enzyme mix. (B) LR reaction facilitates recombination of an attL substrate (entry clone) with an
attR substrate (destination vector) to create an attB-containing expression. This reaction is
catalyzed by LR Clonase™ II enzyme mix. (Figure adopted from Invitrogen User Manual 250749)
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Figure 21. Plasmid map of pYSH5.
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Figure 22. Plasmid map of pYSH7.
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Figure 23. Plasmid map of pYSH6.
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Figure 24. Plasmid map of pYSH8.
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Figure 25. Plasmid map of pYSH9.
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of the vector expressing His6-tagged Shr protein from S. dysgalactiae. A 3.6-kb DNA
fragment containing Shr coding sequence (except the N-terminal leader peptide and the Cterminal membrane anchoring segment) was amplified from the S. dysgalactiae chromosome and
cloned into pET101/D-TOPO vector (Invitrogen). The recombinant clone was selected on
ampicillin (100 µg/ml) and confirmed by restriction enzyme and PCR analysis. The resulting
plasmid, pYSH9 (Fig. 25), expresses His6-tagged Shr fusion protein under the control of T7
RNA polymerase promoter.

Overexpression and purification of Shr proteins. His6-Shr (pCB1) (Bates, Montanez et al.
2003) was expressed and purified as described in Chapter I. The expression of His6-MBP
proteins from pYSH6 and pYSH8 and of Shr-His6 from pYSH9 were induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) and purified as previously described (Fisher,
Huang et al. 2008). The expression of Strep-NTD (pEB10), Strep-NTD-NEAT1 (pEB11) or
Strep-NEAT2 (pHSL2) (Ouattara, Bentley Cunha et al. 2010) were induced with 200 ng/ml
anhydrotetracycline overnight at 28 ºC. E. coli cells were harvested, resuspended in the lysis
buffer (100 mM Tris-HCl pH 8, 500 mM sucrose, 1 mM EDTA) containing 0.5 mg/ml lysozyme,
0.5% β-D glucopyranoside and protease inhibitor cocktail (Complete, mini-EDTA-free, Roche)
and lysed by gentle sonication. The cell debris was centrifuged and the cleared lysate was then
applied to a Strep-Tactin Superflow column (IBA) with a 5 ml bed volume and purified using
FPLC. A step gradient elution program was applied and the Strep-tag proteins were eluted with 5
column volumes of 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM
desthiobiotin. The eluted proteins were analyzed by 10% SDS-PAGE and Western blot using
antibody specific for Shr, His-tag, Strep-Tag or MBP as described previously (Bates, Montanez
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et al. 2003). The purified proteins underwent dialysis in PBS (pH 7.4) in 1: 40,000 ratio to
remove the immidazole from the protein solution. Protein concentrations were measured using
the Modified Lowry Protein Assay kit (Pierce Biotechnology) and aliquots were stored at -20 ºC
for further study.

Antibodies. Rabbit polyclonal antibodies against GAS type-specific carbohydrates, fibronectin
and laminin were purchased from Abcam, plc. Rabbit polyclonal antibodies against M protein
type 49 were described in chapter I. Rabbit antisera were raised against purified His6-MBPNEAT1, His6-MBP-NEAT2, Strep-NTD and the Shr-His6 protein from S. dysgalactiae. Antisera
for all proteins were obtained following previously described protocols (Bates, Montanez et al.
2003). Briefly, the purified proteins (~1 mg) were emulsified with Freund’s complete adjuvant
(Sigma) and injected each into female New Zealand rabbit. Each rabbit was subsequently
immunized with two booster injections in Freund’s incomplete adjuvant (Sigma), at two weeks
intervals. Serum samples were collected one week after each booster to monitor titer
development. The specificity of each antiserum was verified by Western Blot and ELISA and the
titer was determined by ELISA. This protocol was approved by the Georgia State University
Institutional Animal Care and Use Committee.

Enzyme-linked Immunoabsorbent Assays (ELISA). The following ELISAs with immobilized
proteins or whole cells were performed. (i) Ligand binding by immobilized Shr domains. This
assay was used to investigate binding between various host proteins and isolated Shr domains.
96-well EIA/RIA microplate wells (Costar, Corning) were coated overnight at 4 ºC with 20
pmole of purified Shr proteins, washed and blocked with PBST-5% skim milk. Ligands in
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increasing concentrations (in PBST-1% skim milk) were allowed to react with the coated wells
for 1 h at 37 ºC. A ligand-specific antibody (diluted in PBST-1% skim milk) was added to the
wells and the plates were incubated for 1 h at 37 ºC. The wells were then washed with PBST and
binding was detected with alkaline phosphatase-conjugated secondary antibody (Sigma) diluted
in PBST-1% skim milk. The chromogenic reaction was allowed to develop for 30 min following
the addition of the pNPP substrate (KPN). Plates were then read at 405 nm using an automated
reader. (ii) Antiserum binding to immobilized bacteria. This assay was used to study the
surface accessibility of Shr proteins. GAS cells at OD600 = 0.7 were harvested, washed with PBS
and immobilized overnight at 4 ºC onto 96-well EIA/RIA microplate wells. Excess cells were
aspirated and the plates were washed with PBST. After blocking with 5% skim milk in PBST for
1 h at 37ºC, the wells were washed with PBST and incubated with primary antibodies for 1h at
37ºC. The microplates were next washed with PBST and the antigen-antibody binding was
detected with AP-conjugated secondary antibodies as described above.

Mouse passive immunization and infection.
For passive immunization, 100 μl of Shr specific antiserum or normal rabbit serum (NRS) was
mixed with 400 μl PBS and administrated intraperitoneally. MGAS5005 cells at the midlogarithmic phase (OD600 = 0.7) were harvested, washed and resuspended in saline. Cell
concentration was determined by microscopic counts and verified by plating. Mice were infected
with 0.1 ml of bacterial suspension (5x107 cfu) 4-5 hr after the antiserum injection and were
checked four times a day after challenge. Animals exhibiting signs of severe distress were
euthanized and counted as dead. All experiments were repeated three times. These experiments
were conducted according to protocols approved by the Georgia State University Institutional
Animal Care and Use Committee.
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Opsonophagocytic Killing Assay
This assay was performed as described in Chaper II. Essentially, ZE491 GAS cells (OD600 = 0.7)
were harvested and washed. A total of 0.1 ml of diluted (1: 200,000) cells were added into 0.5 ml
of fresh rabbit blood, together with 0.1 ml of rabbit Shr specific antiserum or NRS (as control)
and were incubated with gentle inverting at 37ºC for 3 h. Surviving bacteria were enumerated by
plating for viable counts. Opsonization expressed as the percentage of reduction in mean CFU
was calculated as [1 – (CFU in the presence of Shr antiserum)/ (CFU in the presence of NRS)] x
100 (Olive, Sun et al. 2006).
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Table 2. Oligonucleotide primers used in Chapter III.
Name

Sequence (5’-3’)

Location

ZE353

gagaacctgtacttccagtcttatcaagcaggtgaggtttct

TEV-NEAT1

ZE354

ggggaccactttgtacaagaaagctgggtattaatcatcagtttctacctgataacc

attB2-NEAT1

ZE355

ggggacaagtttgtacaaaaaagcaggctcggagaacctgtacttccag

3’MBP-TEV

ZE356

gagaacctgtacttccaggagaacggccttagagcattaaat

TEV-NEAT2

ZE357

ggggaccactttgtacaagaaagctgggtattattgtggattattagtttctttgac

attB2-NEAT2

ZE410

caccatgcaattagcgggaaaacaatac

Shr
(S. dysgalactiae)

ZE411

gcgattagggctatctttaaattttgg

Shr
(S. dysgalactiae)
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Table 3. Plasmids used in Chapter III.
Reference or
Plasmid

Description

source

pDONR™ 221

Gateway® donor vector for cloning entry vectors

Invitrogen

pYSH5

Entry vector carrying the NEAT1 domain from NZ131

This study

pYSH6

Entry vector carrying the NEAT2 domain from NZ131

This study

pDEST-HisMBP

®

Gateway destination vector for cloning MBP fusion proteins

Addgene
(Nallamsetty,
Austin et al. 2005)

pYSH7

Expression vector for the His6-MBP-NEAT1 fusion protein

This study

pYSH8

Expression vector for the His6-MBP-NEAT2 fusion protein

This study

pET101/D-TOPO

Directional TOPO cloning vector for cloning C-terminal His6

Invitrogen

tagged protein
pYSH9

Expression vector for the Shr-His6 (S. dysgalactiae)

This study

pCB1

Expression vector for the His6-Shr (S. pyogenes)

(Bates, Montanez
et al. 2003)

pEB10

Expression vector for the Strep- NTD (S. pyogenes)

(Ouattara, Bentley
Cunha et al. 2010)

pEB11

Expression vector for the Strep-NTD-NEAT1 (S. pyogenes)

(Ouattara, Bentley
Cunha et al. 2010)

pHSL2

Expression vector of the Strep-NEAT2 (S. pyogenes)

(Ouattara, Bentley
Cunha et al. 2010)
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RESULTS

The NEAT 2 mediates most of Shr binding to ECM.
We have recently found that Shr functions as an adhesin and binds host fibronectin and laminin.
To determine the domains contributing to the ability of Shr to bind protein components of ECM,
immobilized Shr, NTD, NTD-NEAT1 and NEAT2 were allowed to react with the ECM
components using ELISAs. Ligand binding was detected with antibodies specific for fibronectin
or laminin. When fibronectin was added in the course of increasing concentrations to the
immobilized proteins, Shr as well as the recombinant fragments NTD-NEAT1 and NEAT2
bound to it in a concentration-dependent then a saturated manner (Fig. 26A). The NEAT2 protein
demonstrated the highest binding to fibronectin, while only low level binding was seen in NTDNEAT1. No interactions with fibronectin were demonstrated by the immobilized NTD protein.
These observations suggest that NEAT regions mediate the observed Shr binding to fibronectin.
Similar observations were made with laminin. As shown in Fig. 26B, Shr and NEAT2 proteins
bound to laminin, while no significant binding to laminin was observed by the NTD or NTDNEAT1. In short, these observations indicate that while both Shr NEAT domains contribute to
the interaction with ECM components, the NEAT2 domain plays a major role in the ECMbinding activity of Shr.
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Figure 26. Binding of extracellular matrix proteins by Shr.
ELISA assays show fibronectin (A) and laminin (B) binding by Shr (crosses) and NEAT2 (dots).
NTD-NEAT1 (triangles) slightly bound fibronectin but did not bind to laminin. In contrast, NTD
(squares) or BSA (diamonds) did not bind to fibronectin or laminin. The plates were coated with
rShr or Shr fragments and subsequently reacted with increasing concentrations of fibronectin or
laminin as described in Materials and Methods. Each data point represents the average of
triplicates of at least 3 independent repeats.

100
Production of antisera to Shr domains with high titers
Separate Shr domains mediate the protein binding to different ligands: the NTD binds to
hemoglobin while the NEAT domains bind to heme and host ECM protein components
(Ouattara, Bentley Cunha et al. 2010). To further investigate the contribution of each domain to
Shr function and role as a protective immunogen, antibodies specific for separated Shr regions
were generated. We previously found that the NEAT domains are insoluble and accumulate in
inclusion bodies when they are overexpressed as separate protein fragments. To increase
solubility, we cloned NEAT1 and NEAT2 as fusion proteins to MBP under T7 RNA polymerase
promoter system (pYSH6 and pYSH8 respectively). A previously described Strep-NTD protein
(Ouattara, Bentley Cunha et al. 2010) and the two NEAT fusion proteins were overexpressed and
purified by affinity chromatography. The purified proteins were used to immunize rabbits. Serum
samples were collected a week after each antigen administration and titer development was
monitored by ELISA. Antibody titers were defined as the serum dilution producing the same
OD405 at 2 times of the background level (i.e. the reading obtained with serum collected from the
same rabbit before immunization). The titer of anti His6-MBP-NEAT1 and anti-NTD are 6.25 x
106 while the titer of anti His6-MBP-NEAT2 is 1.25 x 106. Antigen recognition and specificity of
each antiserum were analyzed by Western blot assay and ELISA. BSA was used as a negative
control. To exclude the interactions with the MBP portion of the His6-MBP-NEAT1 and His6MBP-NEAT2 fusion proteins, the antisera were reacted with Strep-NTD, Strep-NTD-NEAT1
and Strep-NEAT2 in addition to the antigen used in vaccination and the full-length Shr protein
(Fig. 27).
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The NTD antiserum reacted strongly (~26-fold over the background) and equally with the fulllength Shr and the Strep-NTD, suggesting that this domain is well accessible to antibody even
when it is presented as part of the entire Shr protein. Surprisingly, the NTD antiserum
crossreacted with both of the NEAT domains. Its reaction with the NEAT2 fragment was the
strongest (4-fold above the background) (Fig. 27A). His6-MBP-NEAT1 antiserum reacted with
both NEAT1 and MBP, as expected. This antiserum was specific for the NEAT1 domain and did
not demonstrate significant interaction with the isolated NTD or NEAT2 proteins (Fig. 27B).
Anti His6-MBP-NEAT1 also interacted with the full-length Shr, however, this reaction was
modest (5-fold above the background) comparing to the reaction of the NTD antiserum.
Therefore, NEAT1 is at least partially available for antibody in the intact Shr protein. His6-MBPNEAT2 antiserum reacted with both NEAT2 and MBP (Fig. 27C). Like the anti His6-MBPNEAT1, the antiserum for NEAT2 appeared specific and did not show significant interaction
with NEAT1 and NTD. The Anti His6-MBP-NEAT2 recognized the full-length Shr, producing a
signal that is 4-fold over the background, and thus demonstrated that this domain is also
available on the surface of the full-length Shr.
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(A) Anti-NTD

(B) Anti His6-MBP-NEAT1
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(C) Anti His6-MBP-NEAT2

Figure 27. Specificity of Shr domain antibodies.
The Shr protein or MBP-fusion proteins were immobilized in equal molarity onto microtiter
plates and allowed to ract with antisera raised with isolated Shr domains using ELISA.Antisera
to the following proteins were used: strep-NTD (A), His6-MBP-NEAT1 (B) and His6-MBPNEAT2 (C). BSA and MBP serve as controls for background signal. FL, full-length Shr; NTD,
N-terminal domain; NTD-N1, NTD-NEAT1 fragment; N2, NEAT2 domain; MBP-N1, His6MBP-NEAT1 protein; MBP-N2, His6-MBP-NEAT2 protein.
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Surface presentation of Shr domains
The antibodies raised for isolated Shr domains were used to determine the availability of separate
Shr regions on GAS surface by ELISA with immobilized GAS cells (Fig. 28). Commercially
available antibodies for GAS surface carbohydrates and NRS were used as positive and negative
controls respectively. The antiserum reaction with cells of the wild type strain (NZ131) was
compared to that with the mtsR mutant (ZE491), in which Shr expression is upregulated. As
expected, the carbohydrate-specific antibody produced a clear signal (~ 3-fold above the
background) in both of the tested strains. The antiserum raised against the full-length Shr
generated a reaction that was 2- and 4-fold above the background with NZ131 and ZE491
respectively. This demonstrates that, as we reported in Chapter II, Shr is readily available on
GAS surface. However, in the wild type strain, only the NTD antibody reacted with the
immobilized cells, and no significant reaction was observed with either NEAT1 or NEAT2
antiserum. Repetition of the analysis with cells that overproduced Shr (ZE491) allowed the
detection of the receptor by all of the tested antisera. While the strongest reaction was observed
with anti-NTD (OD405 = 1.35), both NEAT1 and NEAT2 antisera reacted effectively with the
immobilized cells (OD405 = 0.3 and 0.33 respectively). Therefore, all 3 domains appear to, at
least in part, transverse the thick cell wall and are available on the surface. The reduced
efficiency of NEAT1 and NEAT2 antisera when compared to anti-NTD or anti-Shr could result
from the lower expression of Shr in the wild type strain. Alternatively, a surface protein that is
missing in the mtsR mutant might mask NEAT1 and NEAT2 domains in the wild type strain.
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Antibody binding to whole GAS cells
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Figure 28. Surface presentation of Shr domains by whole cells.
Cells of the GAS wild type strain NZ131 and the mtsR mutant ZE491 were allowed to react with
Shr antisera using ELISA with immobilized bacteria. Normal rabbit serum (NRS) serveed as the
negative control. Antisera raised with the full-length Shr (anti-Shr), strep-NTD (anti-NTD), His6MBP-NEAT1 (anti-N1), His6-MBP-NEAT2 (anti-N2) and GAS carbohydrate antibody (antiGAS) were used.
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Passive immunity with antisera raised against isolated Shr domains
Our previous studies showed that rabbit antiserum raised against the full-length Shr protects
naive mice from GAS infection. Pretreatment of mice with Shr hyper immune serum (with a titer
of 106) prior to intraperitoneal infection of MGAS5005 (M type 1) or MGAS315 (M type 3)
increased mice survival 2-3 folds when compared to mice administrated with NRS. Some of the
Shr domains are shared by proteins from important Gram-positive pathogens. This raises the
possibility of developing broad protection based on Shr fragments. We therefore asked which of
Shr regions is protective in a passive immunization model. These experiments were performed as
described in chapter II, except for that the Shr antibodies were replaced by domain antisera. Mice
were treated with NRS, NTD, NEAT1 or NEAT2 antiserum 4-5 hours prior to intraperitoneal
infection with 5x107 cfu of MGAS5005 strain and monitored for 5 days. The end point survival
rate of mice administrated with the NTD, NEAT1 or NEAT2 antisera were 60%, 27% and 27%,
respectively, whereas 40% survival rate was observed with the control mice that were treated
with NRS (Fig. 29). Therefore, unlike the protection observed with antiserum raised against the
full-length Shr, none of the tested antibodies significantly defended mice from GAS. The
survival curve of mice treated with anti-NTD was not statistically different from the mock
vaccinated mice. Surprisingly, mice administrated with NEAT1 and NEAT2 antisera showed
lower survival rate (27% and 27%, respectively) than the control group (40% survival rate) and
the group treated with anti-NTD (60%). Therefore, it appears that the antisera specific for the
NEAT domain sensitize the mice for GAS infection.
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Figure 29. Passive immunization by Shr domain-specific antibody.
Kaplan-Meier survival curves are shown for mice challenged with 5 x 107 CFU of MGAS5005
strain 4 h after intraperitoneal administration of rabbit Shr antisera. Antiserum for His6-MBPNEAT1 (anti-N1), His6-MBP-NEAT2 (anti-N2), strep-NTD (anti-NTD) or normal rabbit serum
(NRS) were used. The data shown are pooled from three independent experiments (total n=15 for
all groups). The statistical significance was determined by the log-rank test.
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Opsonophagocytosis by antisera raised against isolated Shr domains
The ability of the NEAT1 and NEAT2 antisera to opsonize bacteria in whole blood was
compared to that of the serum raised against the full-length Shr. ZE491 cells were incubated in
whole blood in the presence of different Shr antisera or NRS. GAS viable counts were
determined following 3 hours of incubation in blood. As reported before, Shr antiserum resulted
in a significant bacterial opsonization (70%  17 %) in comparison to NRS (Fig. 30). A similar
reductions in bacterial survival was found in cultures that were treated with NEAT1 (69% +
29%) or NEAT2 (85% + 2%) antiserum, respectively.

Production of anti-Shr from S. dysgalactiae
S. dysgalactiae codes for an Shr orthologue that shares the same molecular architecture with
GAS Shr (See Fig. 18). To begin investigating the role of this protein in pathogenesis, an
antibody against this protein was therefore generated. A His-tagged recombinant protein (132
kD) was constructed, over-expressed, purified and administrated to rabbits. The development of
titers was monitored from the rabbit serum collected a week after each injection or boost. One
week after the final immunization, the final IgG titers were determined as 1x106 by ELISA.

109

100
90

Opsonization(%)

80
70

60
50
40
30
20
10
0
NRS

anti-Shr

anti-MBP-N1

anti-MBP-N2

Figure 30. Opsonization of bacteria with Shr domain-specific antibodies.
ZE491 cells were incubated in rabbit whole blood in the presence of rabbit antiserum for Shr,
His6-MBP-NEAT1, His6-MBP-NEAT2 or normal rabbit serum (NRS). Bacterial growth after 3 h
of incubation with Shr antiserum was compared with that in the presence of the control NRS.
The mean opsonization percentage (measured as the percentage reduction in CFU) derived from
4 independent experiments is shown; the standard deviation (SD) is represented by the error bar.
(The data of NRS and anti-Shr were previously described in chapter II.)
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DISCUSSION
The protein domains of Shr in GAS or its orthologues in other Streptococci have been studied by
our laboratory and other investigators. These studies have largely focused on Shr binding to
hemoglobin and heam (Zhu, Liu et al. 2008; Meehan, Burke et al. 2010; Ouattara, Bentley Cunha
et al. 2010). In Chapter I, we determined that in addition to its role in iron acquisition, Shr binds
to fibronectin and laminin and functions in adherence. However, the mechanisms of Shr binding
to ECM remained unknown. In chapter II, we demonstrated that Shr is a protective antigen in
GAS, but the involvement of the separate domains in the induced immunity was not illustrated.
In this chapter, we investigated Shr functional domains focusing on the NTD, NEAT1 and
NEAT2 regions. We localized the binding to fibronectin and laminin to the NEAT domains of
Shr and showed that it is mostly mediated by NEAT2. We raised antisera for separate regions of
Shr and used them to show that the NTD, NEAT1 and NEAT2 domains transverse GAS
peptidoglycan layer and are exposed on the surface. In addition, we tested the ability of the
domain-antibodies to defend mice and to opsonize bacteria. The Shr antibodies were bactericidal
in whole blood. However, none of the antisera were able to protect mice effectively from
infections. Surprisingly, both NEAT1 and NEAT2 antibodies appeared to increase mice
sensitivity to GAS infections.

NEAT2 strongly interacts with both fibronectin and laminin molecules, while NEAT1 binds only
to fibronectin and with a weaker affinity (Fig. 26). Therefore, NEAT2 appears to play more
significant role in Shr interactions with the ECM. This is the first time that NEAT domains are
found to be part of MSCRAMMs in GAS. Ligand interactions with the common fibronectin
binding proteins in GAS had been extensively studied (Talay, Valentin-Weigand et al. 1994;
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Jaffe, Natanson-Yaron et al. 1996) . For example, SfbI and F2 bind fibronectin through a tandem
-zipper binding mechanism using fibronectin-binding repeats (Schwarz-Linek, Werner et al.
2003). These repeats are 35-40 residues long and are located at the C-terminal half of the
adhesin. A second region found immediately upstream to the repeats acts to enhance SfbI affinity
to fibronectin (Fig. 19). The number of the fibronectin-binding repeats in SfbI ranges from 2 to 7
in different strains, suggesting that the protein evolution involves domain deletion and
duplication events (Towers, Fagan et al. 2003). Protein F2 is only functionally related to SfbI and
is expressed in a small subset of GAS strains that do not express SfbI. Protein F2 has two
fibronectin binding domains in its C-terminus, which are ~100 aa residues apart. One of these
regions is composed of three consecutive repeats of 21-37 residues and the other is made of ~100
non-repeated residues. Shr lacks all the binding repeats described for GAS or other bacteria and
thus appears to use a new protein pattern and mechanism to bind fibronectin.

In addition to the interactions with ECM components, both of the NEAT domains in Shr bind
heme, and therefore exhibit an unusual ligand binding property. The only example of a NEAT
domain that binds ligand other than heme and heme-containing proteins is the single NEAT
domain of the staphylococcal IsdA protein. IsdA is an iron-regulated adhesin that interacts with a
broad spectrum of ligands, including heme, several heme proteins, fibronectin and fibrinogen
(Clarke, Wiltshire et al. 2004). IsdA binds these ligands with a single NEAT domain. Therefore,
some NEAT domains may have a binding motif for some ECM proteins. The crystal structure of
several NEAT domains including that of IsdA (PDB entry 2ITF) has been solved (Pilpa, Fadeev
et al. 2006; Grigg, Vermeiren et al. 2007; Sharp, Schneider et al. 2007). These studies revealed
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an immunoglobulin-like -sandwich fold with a large hydrophobic heme-binding pocket (Fig.
31). The Ig-like fold contains eight -strands, forming two -sheets in the sandwich.

To learn more about the possible fold of Shr NEAT domains, we looked for homologous targets
in the Swissprot database using BLAST (Basic Local Alignment Search Tool). No matches with
significant similarity in primary sequence were found. The two NEAT domains in Shr share
30.9% identity encompassing 55 residues and only ~20% identity with other NEAT domains in
the database. We performed structure alignment of Shr NEAT1 and NEAT2 by BLAST analysis
with PDB (Protein Domain Bank). While NEAT1 matched two domain models with 27%
sequence similarity, NEAT2 failed to match any modeled structure. The two models that
matched NEAT1 are that of IsdC protein from S. aureus. One is a crystal structure with heme
bound that was solved by X-ray fractionation (PDB entry 2O6P) and the other is in solution with
zinc protoporphyrin, which was predicted by NMR (PDB entry 2k78). IsdC is the central heme
shuttle protein in the Isd system. It receives heme from IsdA, IsdB and IsdH and delivers it to the
cognate ABC transporter. Based on the information of 2O6P given by PDB, we used two
structure modeling servers to predict the structure of a heme-bound NEAT1 (Fig. 32). This
analysis predicts that NEAT1 shares notable structural similarity with that of IsdA and suggests
that NEAT1 has an immunoglobulin-like -sandwich fold composed of eight -strands that form
the heme-binding pocket.
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Figure 31. Crystal structure of heme-bound IsdA NEAT domain from Staphylococcus
aureus.
Secondary structure of the IsdA NEAT domain bound with the heme (PDB entry 2ITF). Yellow
ribbons represent -sheets, pink ribbons represent -helix. Heam is shown in sticks within the
binding pocket (Figure adopted from Grigg, Vermeiren et al. 2007 and viewed by Jmol
program).
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Figure 32. Predicted structure of Shr NEAT1 domain.
(Left) The structure of NEAT1 domain with heme bound is predicted based on the template,
IsdC NEAT domain from S. aureus (PDB entry 2O6P), by Structure and Alignment Server
(http://bmcc3.cs.gsu.edu/) and viewed by RasMol program. (Right) The structure of NEAT1
domain is predicted based on the same template by Protein Homology/analogy Recognition
Engine v.2 (Phyre2) (Kelley and Sternberg 2009) (right) and viewed by Jmol program. Yellow
ribbons represent -sheets, pink ribbons represent -helix and blue color represents turns. The
gray stick represents the structure of heme (left).
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As in all NEAT domain characterized to date, the suggested structure of Shr NEAT1 is rich with
-strands. -sheets are found in the typical fibronectin binding region of several bacterial
receptors and are a structural feature that is important for ligand interaction (Schwarz-Linek,
Werner et al. 2003). Fibronectin binding by bacterial receptors involves a -strand that lines up
in an antiparallel arrangement to the triple-strand of the F1 segment in the fibronectin, forming
an extended tandem -zipper (Fig. 19). It is thus conceivable that some NEAT domains also bind
fibronectin with one of the eight -strands at either side of the -sandwich (Fig. 32). Out of the
two NEAT domains in Shr, NEAT2 is the key binder to the ECM. It seems possible that the Shr
evolved via duplication of an ancestor NEAT domain followed by divergent evolution that led to
domains with separate ligand activity. Domain duplication may facilitate an increased sensitivity
to ligands that are present at low concentration such as heme, or it may enhance bacterial
interactions with host surface (Andrade, Ciccarelli et al. 2002).

Our analysis demonstrated that the antisera raised with isolated NEAT1 or NEAT2 were quite
specific and did not interact significantly with the other NEAT domain (Fig. 27). These
observations are surprising as both protein modules are expected to share similar fold. Therefore,
distinctive structural characteristics are found in each domain, which lead to unique antigenic
determinants. Surprisingly, immunization with Shr NTD produced an antiserum which crossreacted with both NEAT1 and NEAT2 regions (Fig. 27). Shr NTD does not have significant
sequence homology with non-Shr proteins in the database. However, it contains two copies of
domain with unknown function (DUF1533) that is found in various copies in mostly hypothetical
proteins from the firmicutes phylum. It seems possible that the NEAT domain, which is widely
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spread in the Firmicutes, and the DUF1533 share a common ancestor, or that one had evolved
from the other. Additional studies are needed to map the epitopes that are shared by Shr NTD
and the NEAT domains and to further explore this hypothesis.

We examined the surface architecture of Shr domains in GAS NZ131 (wild type) and ZE491
(mtsR mutant) using the antibodies generated with separate Shr regions (Fig. 28). Only the NTD
antibody interacted with NZ131 cells, while no reaction with the NEAT1 or NEAT2 antisera was
observed. However, a significant reaction between both NEAT antibodies and GAS cells was
observed when ZE491 cells were used. Since both antisera are specific and recognize only the
NEAT domain used to produce them, this observation indicates that both NEAT domains are
exposed at least in part, outside of GAS cell wall. Due to inactivation of mtsR, which represses
the shr gene, the expression of Shr in ZE491 is 3-4 folds higher than that in NZ131. The failure
of the NEAT antisera to detect Shr in NZ131 may result from the lower expression of Shr in this
strain. It is also possible that Shr NEAT domains are covered by a separate surface protein that is
missing in the mtsR mutant strain. The NTD antibody produces a very strong signal with both the
wild type and mtsR mutant strains. This observation suggests that the NTD of Shr is well
exposed on the bacterial surface. However, cross reactions with other Shr regions may have also
contributed to the interactions between the NTD antiserum and GAS cells.

Because of their surface presentation and contribution to bacterial colonization, NEATcontaining proteins provide a collection of candidates for vaccine development against several
Gram-positive pathogens. The protective potential of NEAT proteins from S. aureus has been
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examined in several vaccine models. For example, a multivalent vaccine that involves IsdA and
IsdB protects mice from kidney infections by staphylococcus in both active and passive
immunization protocols (Stranger-Jones, Bae et al. 2006). Vaccination with IsdB induced rapid
antibody responses in rhesus macaques and defended mice from S. aureus in a sepsis infection
model (Kuklin, Clark et al. 2006). Immunization with IsdA and IsdB antibodies protected mice
from staphylococcal abscess formation and lethal challenge (Kim, DeDent et al. 2010). In
addition, mucosal immunization with IsdA-chimera protein induces antigen-specific humoral
response in mice (Arlian and Tinker 2011). In Chapter II, we reported that Shr elicit immunity
from GAS in mouse infection model. In this chapter, we tested the antigenic and protective
potential of separate Shr domains. Hyperimmune sera were obtained for each of the tested
antigens, indicating that they are all immunogenic. However, none of these sera were able to
effectively defend mice from GAS infection in passive vaccination experiments. Administration
of the NTD antiserum resulted in 60% survival, which is higher but not statistically significant
than the survival rate of the control group (40%) (Fig. 29). The NTD mediates Shr binding to
hemoglobin (Ouattara, Bentley Cunha et al. 2010), which is the first step of heme uptake from
the host. Therefore, anti-NTD may prevent hemoglobin binding and thus interferes with the iron
uptake process during infections. The NTD contains two copies of DUF1533, which is found in
several repeats in putative proteins from Clostridia and in two species of Paenibacillus (Fig. 18).
Hence, the NTD domain may allow the development of broad-spectrum protection. More
experiments are needed to examine the effectiveness of NTD based vaccine.

Mice treated with NEAT1 or NEAT2 antiserum showed only 27% survival rate at the end point.
This survival rate is lower than that of the control group that was treated with NRS. Therefore, it
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seems that these antisera augmented the severity of GAS infections. The lack of protection might
be the result of steric hindrance. The weak interactions of the NEAT antisera with wild type
GAS, suggest that the domains may be only partially accessible. It is also possible that the
protein fold of isolated fragments is different from that in the full length Shr. Therefore, the
resulting antibodies may be less effective in interacting with Shr. The increased mortality in the
mice treated with the NEAT antisera is surprising and the mechanism involved is not clear. It is
possible that these antibodies react with host components and thus impair the host immune
response. A structural modeling using the Protein Homology/analogy Recognition Engine v.2
(Phyre2) (Kelley and Sternberg 2009) suggests that a region in Shr that contains the LRR and
NEAT2 shares the same fold as toll-like receptors (TLR). It thus seems possible that the NEAT
antisera facilitate an autoimmune reaction with TLRs and trigger the production of harmful
inflammatory cytokines.

A significant reduction in the number of viable bacteria in whole blood was found in the
presence of antiserum against Shr, NEAT1 and NEAT2 in comparison to NRS (77%, 69% and
85%, Fig. 30). Therefore, all the tested antisera were similarly effective in opsonizing GAS.
This observation is intriguing, considering that the NEAT antisera reaction with whole GAS cells
is weaker than that of anti-Shr antibody (Fig. 28). It is possible that Shr is upregulated in GAS
while growing in the blood and that this overexpression facilitates stronger interaction with the
antisera. The observed opsonization by the NEAT antibodies also supports the proposal that an
autoimmune response rather than inability to interact with GAS cells is responsible for the
observed failure to protect mice from GAS infections. Additional work, however, is required to
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characterize GAS expression profile in different infection sites (such as blood, intraperitoneal
cavity etc.) and to illustrate the interaction of Shr antibodies with GAS and the host components.
In conclusion, this chapter dissects Shr at the submolecular level and illustrates the receptor
interactions with host components and antigenic potential. We have mapped the ECM binding
region in Shr and suggested a possible binding mechanism for the interactions with fibronectin.
We tested availability of Shr domains on GAS surface and initiated the identification of
protective regions in Shr.
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GENERAL DISCUSSION

GAS is a dangerous human pathogen that produces a number of simple disease as well as severe
infections and immune complications. The antigenic variability of key surface proteins in GAS
allows this pathogen to escape the host adaptive immune system. As a result, individuals can
experience repeating episodes of GAS infections throughout their life span. The long term goal
of this dissertation is to gain a better understanding of the molecular mechanisms of GAS
virulence, so that new and efficient strategies for prevention and therapy could be developed.
The focus of this work is a conserved surface protein named Shr. Shr is a complex protein that
contains a unique N-terminal region and two NEAT domains with LRR in between. This
dissertation summarizes our investigations of Shr structure and function, its contributions to
GAS interactions with the human host and its antigenic properties. In the sections below, we
discuss our findings and their importance to the field of GAS pathogenesis and vaccine
development.

Shr and adherence
Adherence is an early and critical step in the infection process. GAS can colonize multiple sites
in the human body including the epidermis, various niches at the upper respiratory tract and
many otherwise sterile tissues. This versatility is reflected in the complex array of adhesins used
by GAS. In addition to TA and pili, GAS employs over a dozen of afimbrial adhesins, most of
which are MSCRAMMs that target fibronectin and other ECM components (Patti, Allen et al.
1994). One of the main contributions of this dissertation is the finding that Shr is a part of GAS
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adhesins family. This receptor specifically binds to fibronectin and laminin and contributes to
GAS interactions with epithelial cells (Fig. 7, 8, and 10).

Shr inactivation had only a moderate impact (2 fold) on GAS adherence to the human epithelial
Ep-2 cell line (Fig. 10). This cell line was originally thought to be derived from an epidermoid
carcinoma of the larynx, but was subsequently traced to HeLa cell contamination. Differently
from our studies with Ep-2, significantly larger contribution of Shr to attachment (15 fold) was
found when the NCIH292 cell line was tested (Appendix A, Fig. 33). NCIH292 cells are derived
from human lung cells and therefore may represent a better adherence model for a mucosal
pathogen such as GAS. Shr affinity for specific tissues indicates that in vivo the receptor would
likely contribute to GAS interactions with host surface only in certain infection sites.

Shr is the first adhesin in GAS that was found to be expressed in response to iron limitation.
Other adhesins, such as the M protein, SfbI or SOF are regulated by other environmental cues
such as atmospheric compositions, temperature and/or nutrient availability. Therefore, while
GAS codes for multiple adhesins, only a subset is likely to be expressed at certain niches in the
body. Since tissue models are able to reproduce only some of the conditions that bacteria
experience during infection, a better evaluation of Shr contribution to adherence could be
achieved using animal models. Indeed, an shr mutant is significantly disadvantaged in
comparison to the wild type strain in an intramuscular zebrafish infection model (Fig. 12).
However, this infection model does not differentiate the relative contribution to iron uptake from
that to adherence by the pleiotropic Shr.
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Fibronecting binding by Shr
In vitro, Shr binds directly and specifically to fibronectin and laminin, but not to collagen or
fibrinogen. Thus, Shr is selective and interacts with only a subset of ECM components (Fig. 7
and 8). Furthermore, L. lactis cells expressing Shr gained the ability to exclusively interact with
fibronectin (Fig. 9B). These observations demonstrate that Shr mediates whole-cell binding to
the ECM and supports its role as a GAS MSCRAMM. Analysis of Shr domains showed that both
of the Shr NEAT domains contribute to its interactions with ECM components; however,
NEAT2 plays a more prominent role in this process (Fig. 26). The single NEAT domain of IsdA
from S. aureus also binds fibrinogen and fibronectin in addition to heme (Clarke, Wiltshire et al.
2004). Therefore, like the staphylococcal IsdA, Shr uses the NEAT modules for adherence in
addition to heme scavenging. It is interesting that the NEAT in IsdA binds hemoglobin and
hemoglobin-haptoglobin complexes. However, this activity in Shr is localized to a separate
region in the N-terminal part of the receptor (Ouattara, Bentley Cunha et al. 2010).

Our work provided only the second example for ECM binding by NEAT domains. The
mechanisms by which fibronectin and laminin bind to NEAT are still not known. Fibronectin
binding by other MSCRAMMs such as SfbI is mediated by a tandem -zipper mechanism
(Schwarz-Linek, Werner et al. 2003). This model involves antiparallel deposition of -strands of
the bacterial receptor to -strands from the F1 region of fibronectin. Characterized NEAT
domains and the predicted fold of Shr NEATs contain several -strands (Fig 31 and 32). It seems
feasible that like in other bacterial receptors, one or more of the -strands in NEAT participate in
fibronectin binding. It is important to note, however, that only a few NEAT domains bind
fibronectin and that significant differences in the affinity to fibronectin are found between Shr
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NEAT1 and NEAT2. Therefore, additional work is needed to determine exactly how the NEAT
module allows binding of non-heme ligands and to identify the specific properties that are
required for fibronectin binding by a subset of NEAT domains.

Shr Topology
Typical Gram-positive MSCRAMMs have an N-terminal leader peptide, one or more repetitive
motifs that mediate ligand binding and a C-terminal transmembrane domain with the cell wall
anchoring motif LPX[T,S,A]G (Patti, Allen et al. 1994). We localized Shr, which lacks the
sortase anchoring motif, to the cell membrane fraction in GAS (Fig. 4). We suggest that the
hydrophobic segment found in the protein carboxy terminus anchors Shr to the membrane.
Nevertheless, Shr is still exposed on the cell surface in both GAS (Fig. 6) and heterologous
Gram-positive hosts such as L. lactis (Fig. 9A). Since the cell membrane resides underneath the
peptidoglycan layers, the extruding portion of Shr protein must pass through the cell wall to
extend to the exterior. Using antibodies raised against separate regions of Shr, we showed that
epitopes from the NTD, NEAT1 and NEAT2 are available for interactions outside of bacterial
surface (Fig. 28). These findings are consistent with the predicted topology of Shr
(Mobyle@Pasteur, http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::toppred). This in silico
analysis suggests that Shr has only two hydrophobic helices; one is located at the N-terminal
leading peptide which is cleaved during export and the other is found at the C-terminus and is
followed by a few charged residues. Together, our observations and analysis suggest that Shr
protrudes through cell wall; the N-terminus of the mature protein and the two NEAT domains are
localized at least in part, at the extracellular environment, while the C-terminus is embedded in
the cell membrane with the charged tail in the cytoplasm. The availability of NEAT2 domain for
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antibody outside of the cell wall is also consistent with the adherence function that we propose
for NEAT2.

The multiple fibronectin-binding proteins expressed by GAS complicate the analysis of Shr
interactions with this ligand in vivo. Therefore, we constructed a number of in-frame deletions in
Shr and expressed the mutants in L. lactis (Appendix B, Fig. 34). Unfortunately, we found that
unlike the full length protein, these shr mutants were not stable in L. lactis. Thus, new
approaches, such as Shr-coated latex beads, are needed to investigate the net effect of Shr on
GAS adherence and invasion (Ozeri, Rosenshine et al. 1998).

Antigenic studies of Shr
A key contribution of this work to the field of GAS pathogenesis is the finding that Shr is a
protective antigen. In silico analysis shows that the shr gene is highly conserved in the available
GAS genomes. This observation together with our finding that Shr protein was expressed on the
surface of many clinical isolates (Table 1) suggest that a vaccine based on Shr may provide a
broad protection against streptococcal diseases. Therefore, Shr vaccine could avert the problems
of M protein-derived vaccines, such as protection against limited serotypes and cross reaction
with host epitopes.

Shr is highly immunogenic. Systemic vaccination with purified full length Shr protein resulted in
robust antibody response in serum (Fig. 13). Also, Shr triggered strong serum response in mice
administrated intranasally with recombinant L. lactis expressing Shr (Fig. 15). Shr conservation
and strong antigenicity are somehow hard to reconcile with the fact that an individual fails to
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mount protective response to GAS and thus may experience multiple infections. It is possible
that while the purified Shr is a strong immunogen, the host response to GAS may be dominated
by other antigens such as the plentiful M protein. Therefore, GAS may use the hypervariable M
protein as a “decoy” immunogen that leads to an immune response that is essentially ineffective
against the wide spectrum of M serotypes. While a measurable IgA response was observed in
mice treated intranasally with Shr-producing L. lactis, the resulting IgA titers were quite weak.
The mucosal immune response to Shr may be improved by using purified protein and alternative
adjuvant.

Both systemic and mucosal vaccination with Shr elicited protection from systemic GAS
challenge by a highly virulent GAS strain (Fig. 14 and 15). These observations are very
promising and indicate that additional studies exploring Shr as vaccine candidate are justified.
They also indicate that Shr vaccine could be administrated by more than one route. Most of GAS
infections are initiated at the upper respiratory tract and the skin. Therefore, testing the ability of
Shr vaccine to protect from mucosal and cutaneous challenges are the logical next steps. Murine
model can serve as a suitable tool for skin infection. Unfortunately, there is no good murine
model for the upper respiratory tract infections produced by GAS. Therefore, experiments for
mucosal protection may require in vivo model in higher animals such as rhesus macaques. The
staphylococcal NEAT protein, IsdB, has been tested in arhesus macaque model and was found to
elicit rapid antibody responses when administrated intramuscularly (Kuklin, Clark et al. 2006).
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Shr antibody defenses against GAS
The efficacy of an antibody can be examined by passive immunization experiments (Dale, Baird
et al. 1994; Sabharwal, Michon et al. 2006). Shr rabbit antiserum effectively defended mice from
systemic challenge by two GAS serotypes (Fig. 16). These findings are impressive, especially
considering that rabbit antiserum was used in these experiments rather than isolated IgGs or
affinity purified Shr antibody. In addition to Shr, two NEAT proteins in S. aureus were identified
as protective antigens. Purified antibodies for IsdA or IsdB defended mice from renal abscess
formation and a lethal intravenous challenge (Kim, DeDent et al. 2010). Unlike Shr antiserum,
IsdA and IsdB antibody do not promote opsonophagocytic killing (Kim, DeDent et al. 2010).
The opsonizing ability of Shr antiserum explains at least in part its protective action (Fig. 17).
Shr antibody appears to be a key component of the host defense. It is most likely to work by
neutralizing Shr on the bacterial surface. The establishment of lethal infection by the i.p. route
used in our study is not likely to require adherence. Thus, the potential anti-adherence properties
of the Shr antiserum may not seem important to GAS defense in this model. Therefore, Shr
antibody may protect mice by interfering with Shr ability to obtain iron. In vitro model for
adherence and growth is needed to further characterize the protective properties of Shr
antiserum.

The survival rate of mice passively immunized with anti-Shr is lower than that of actively
immunized mice (Fig. 14, 15, and 16). The reduced protection by passive vaccination may result
from the absence of T-cell mediated immunity. CD4+ cells are the major pathway for the
development of long-lasting immunity. The CD4+ cells bind to the epitopes presented by
antigen-presenting cells and coordinate the induced immune response. Another limitation of
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passive immunization is that the protection is limited by the amount of antibody and application
time. Additional work is needed to optimize the protocols for passive immunization, which may
in turn enhance the observed protection.

The antisera of NEAT domains are opsonizing and their ability to facilitate bacterial killing in
blood is similar to that of anti-Shr (Fig. 30). However, these antisera failed to protect mice in the
passive immunization. Mice treated with NTD antiserum had a higher survival rate than the
control group, but the difference was small (20%) and not statistically significant (Fig. 29). It is
not clear why the antiserum generated with the full length protein is more protective than the
domain antisera. It seems conceivable that protective epitopes that are found in the full length
Shr may be missing in the isolated domains. In addition, some of the antibody generated against
an isolated domain may not interact with the full length proteins, since the domain may fold
differently and some epitopes are not accessible in the complete receptors. Finally, an effective
defense may require the simultaneous neutralization of several Shr functions and the antibodies
recognizing multiple sites in the protein.

A significant concern is raised from the observation that the antisera for NEAT1 and NEAT2
sensitize mice to GAS infections. We propose that the NEAT domains which have
immunoglobulin-like fold, share epitopes with host proteins. Thus, the NEAT antisera may
induce autoimmune complications. A structural modeling program (Phyre2) suggests that the
LRR-NEAT2 region in Shr folds similarly to the ligand-binding site of toll-like receptors
(TLRs). TLRs are essential components of the innate immune response and are therefore one of
the key factors involved in recognizing and defending against invading pathogens. NEAT
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antibodies may interact with the ligand binding site of TLRs and thus block their activity, which
in turn will attenuate the innate immune system. Alternatively, these interactions may
overactivate the receptor and therefore lead to excessive and harmful cytokine responses. The
effect of NEAT antiserum on host needs to be tested in mice without GAS challenge or with
non-Shr-expressing bacteria in order to begin addressing these concerns.

The efforts for GAS vaccine development has focused mostly on the variable N-terminus of M
protein. However, recent studies examined several conserved epitopes in GAS, these include the
ScpA, cell wall carbohydrates and a few fibronectin-binding proteins (Ji, Carlson et al. 1997;
Kawabata, Kunitomo et al. 2001; Sabharwal, Michon et al. 2006). Several studies have used
modern proteomics and genomics methods and identified new immunogenic determinant in GAS
(Rodriguez-Ortega, Norais et al. 2006; Dale 2008; Steer, Batzloff et al. 2009). In this work, we
demonstrate that Shr is a MSCRAMM that contributes to the progress of GAS pathogenesis
beyond iron acquisition. The conservation of Shr in multiple streptococci and the domains it
shares with other Gram-positive pathogens suggest that Shr may provide broad protection against
GAS and related pathogens. We initiate the investigation of Shr antigenic properties and provide
strong support to the promise of Shr-based vaccine.
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Figure 33. Adherence of GAS to cultured lung cells NCIH292.
Mid-log phase cultures of wild-type strain (NZ131) and shr mutant (ZE4912) were incubated
with confluent NCIH292 cell monolayers for 2 h at 37 ºC under 5% CO2. Unattached bacteria
were removed by washing, cells were detached and lysed, and the number of bound bacteria per
well was determined by plating. Each bar represents the mean number of GAS cells attached as
obtained from at least two independent experiments performed in triplicate. The standard
deviation is expressed by the error bar. The difference between NZ131 and ZE4912 is significant
(P < 0.005).
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Figure 34. Surface presentation of Shr mutants in L. lactis.
L. lactis strains expressing Shr mutants were immobilized in the wells of microtiter plate and
then detected with anti-Shr and anti-L. lactis antibodies in ELISA. Normal rabbit serum (NRS)
serves as negative control, showing the background signal of rabbit serum. MG1363 is the naïve
L. lactis. pJRS700 is the L. lactis strain with the empty vector without inserted shr gene. pXL14
is the L. lactis strain that expresses full-length Shr protein on the surface. pXL20 is the L. lactis
strain expressing a NTD-NEAT1 domain deletion mutant. pYSH1 is the L. lactis strain
expressing a NEAT1 domain deletion mutant. pYSH2 is the L. lactis strain that expresses a
partial NEAT2 deletion mutant. pYSH3 is the L. lactis strain expressing a NEAT2 deletion
mutant. Each bar represents the detection by anti-Shr as from two independent experiments.

